| Year |
Citation |
Score |
| 2024 |
Altman JE, Olex AL, Zboril EK, Walker CJ, Boyd DC, Myrick RK, Hairr NS, Koblinski JE, Puchalapalli M, Hu B, Dozmorov MG, Chen XS, Chen Y, Perou CM, Lehmann BD, et al. Single-cell transcriptional atlas of human breast cancers and model systems. Clinical and Translational Medicine. 14: e70044. PMID 39417215 DOI: 10.1002/ctm2.70044 |
0.458 |
|
| 2024 |
Artham S, Juras PK, Goyal A, Chakraborty P, Byemerwa J, Liu S, Wardell SE, Chakraborty B, Crowder D, Lim F, Strawser CH, Newlin M, Racioppi A, Dent S, Mirminachi B, ... ... Perou CM, et al. Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth. Science Advances. 10: eadp2442. PMID 39331714 DOI: 10.1126/sciadv.adp2442 |
0.411 |
|
| 2024 |
File DM, Abdou Y, Force J, Moore DT, Anders CK, Reeder-Hayes K, Carey LA, Muss HB, Perou CM, Marcom PK, Dees EC. A Phase I Trial of Alpelisib Combined With Capecitabine in Patients With HER2-Negative Metastatic Breast Cancer. Clinical Breast Cancer. PMID 39217059 DOI: 10.1016/j.clbc.2024.08.001 |
0.406 |
|
| 2024 |
Stover DG, Salgado R, Savenkov O, Ballman K, Mayer EL, Magbanua MJM, Loi S, Vater M, Glover K, Watson M, Wen Y, Symmans WF, Perou C, Carey LA, Partridge AH, et al. Association between tumor-infiltrating lymphocytes and survival in patients with metastatic breast cancer receiving first-line chemotherapy: analysis of CALGB 40502. Npj Breast Cancer. 10: 75. PMID 39169033 DOI: 10.1038/s41523-024-00683-x |
0.386 |
|
| 2024 |
Yazdimamaghani M, Kolupaev OV, Lim C, Hwang D, Laurie SJ, Perou CM, Kabanov AV, Serody JS. Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy. Biomaterials. 312: 122750. PMID 39126779 DOI: 10.1016/j.biomaterials.2024.122750 |
0.305 |
|
| 2024 |
Sun X, Kennedy LC, Gonzalez-Ericsson PI, Sanchez V, Sanders M, Perou CM, Troester MA, Balko JM, Reid SA. Associations of immune checkpoint predictive biomarkers MHC-I and MHC-II with clinical and molecular features in a diverse breast cancer cohort. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 39007881 DOI: 10.1158/1078-0432.CCR-24-1286 |
0.441 |
|
| 2024 |
Li Y, Van Alsten SC, Lee DN, Kim T, Calhoun BC, Perou CM, Wobker SE, Marron JS, Hoadley KA, Troester MA. Visual Intratumor Heterogeneity and Breast Tumor Progression. Cancers. 16. PMID 39001357 DOI: 10.3390/cancers16132294 |
0.605 |
|
| 2024 |
Llombart-Cussac A, Pérez-García J, Brasó-Maristany F, Paré L, Villacampa G, Gion M, Schmid P, Colleoni M, Borrego MR, Galván P, Parker JS, Buckingham W, Perou CM, Villagrasa P, Guerrero JA, et al. HER2DX Genomic Assay in HER2-positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from PHERGain Phase II Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38995291 DOI: 10.1158/1078-0432.CCR-24-0464 |
0.615 |
|
| 2024 |
Lorman-Carbó N, Martínez-Sáez O, Fernandez-Martinez A, Galván P, Chic N, Garcia-Fructuoso I, Rodríguez A, Gómez-Bravo R, Schettini F, Blasco P, Castillo O, González-Farré B, Adamo B, Vidal M, Muñoz M, ... Perou CM, et al. Comparative biological activity of palbociclib and ribociclib in hormone receptor-positive breast cancer. Scientific Reports. 14: 16030. PMID 38992220 DOI: 10.1038/s41598-024-67126-2 |
0.436 |
|
| 2024 |
Regner MJ, Garcia-Recio S, Thennavan A, Wisniewska K, Mendez-Giraldez R, Felsheim B, Spanheimer PM, Parker JS, Perou CM, Franco HL. Defining the Regulatory Logic of Breast Cancer Using Single-Cell Epigenetic and Transcriptome Profiling. Biorxiv : the Preprint Server For Biology. PMID 38948758 DOI: 10.1101/2024.06.13.598858 |
0.643 |
|
| 2024 |
Tolaney SM, DeMichele A, Takano T, Rugo HS, Perou C, Lynce F, Parsons HA, Santa-Maria CA, Rocque GB, Yao W, Sun SW, Mocci S, Partridge AH, Carey LA. OptimICE-RD: sacituzumab govitecan + pembrolizumab vs pembrolizumab (± capecitabine) for residual triple-negative breast cancer. Future Oncology (London, England). 1-21. PMID 38922307 DOI: 10.1080/14796694.2024.2357534 |
0.327 |
|
| 2024 |
Han YJ, Liu S, Hardeman A, Rajagopal PS, Mueller J, Khramtsova G, Sanni A, Ajani MA, Clayton W, Hurley IW, Yoshimatsu TF, Zheng Y, Parker J, Perou CM, Olopade OI. The VEGF-Hypoxia Signature is Upregulated in Basal like Breast Tumors from Women of African Ancestry and Associated with Poor Outcomes in Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 38564595 DOI: 10.1158/1078-0432.CCR-23-1526 |
0.616 |
|
| 2024 |
Yazdani A, Yazdani A, Mendez-Giraldez R, Pillonetto G, Samiei E, Hadi R, Lenz HJ, Venook A, Samiei A, Nixon A, Kopetz S, Bertagnolli M, Perou C, Innocenti F. Gene expression biomarkers differentiate overall survival of colorectal cancer upon targeted therapies. Research Square. PMID 38559223 DOI: 10.21203/rs.3.rs-4047331/v1 |
0.374 |
|
| 2024 |
Yazdimamaghani M, Kolupaev OV, Lim C, Hwang D, Laurie SJ, Perou CM, Kabanov AV, Serody JS. Tumor microenvironment immunomodulation by nanoformulated TLR 7/8 agonist and PI3k delta inhibitor enhances therapeutic benefits of radiotherapy. Biorxiv : the Preprint Server For Biology. PMID 38559220 DOI: 10.1101/2024.03.09.584084 |
0.367 |
|
| 2024 |
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, ... ... Perou CM, et al. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials. Jama Oncology. PMID 38546612 DOI: 10.1001/jamaoncol.2023.7304 |
0.7 |
|
| 2024 |
Hamilton AM, Walens A, Van Alsten SC, Olsson LT, Nsonwu-Farley J, Gao X, Kirk EL, Perou CM, Carey LA, Troester MA, Abdou Y. BIRC5 expression by race, age and clinical factors in breast cancer patients. Breast Cancer Research : Bcr. 26: 50. PMID 38515208 DOI: 10.1186/s13058-024-01792-y |
0.468 |
|
| 2024 |
Pascual T, Fernandez-Martinez A, Agrawal Y, Pfefferle AD, Chic N, Brasó-Maristany F, Gonzàlez-Farré B, Paré L, Villacampa G, Saura C, Hernando C, Muñoz M, Galván P, Gonzàlez-Farré X, Oliveira M, ... ... Perou CM, et al. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy. Npj Breast Cancer. 10: 20. PMID 38448600 DOI: 10.1038/s41523-024-00625-7 |
0.4 |
|
| 2024 |
Conte B, Brasó-Maristany F, Hernández AR, Pascual T, Villacampa G, Schettini F, Vidal Losada MJ, Seguí E, Angelats L, Garcia-Fructuoso I, Gómez-Bravo R, Lorman-Carbó N, Paré L, Marín-Aguilera M, Martínez-Sáez O, ... ... Perou CM, et al. A 14-gene B-cell immune signature in early-stage triple-negative breast cancer (TNBC): a pooled analysis of seven studies. Ebiomedicine. 102: 105043. PMID 38447275 DOI: 10.1016/j.ebiom.2024.105043 |
0.623 |
|
| 2024 |
Jiang YZ, Ma D, Jin X, Xiao Y, Yu Y, Shi J, Zhou YF, Fu T, Lin CJ, Dai LJ, Liu CL, Zhao S, Su GH, Hou W, Liu Y, ... ... Perou CM, et al. Integrated multiomic profiling of breast cancer in the Chinese population reveals patient stratification and therapeutic vulnerabilities. Nature Cancer. PMID 38347143 DOI: 10.1038/s43018-024-00725-0 |
0.488 |
|
| 2024 |
Ma CX, Suman VJ, Sanati S, Vij K, Anurag M, Leitch AM, Unzeitig GW, Hoog J, Fernandez-Martinez A, Fan C, Gibbs RA, Watson MA, Dockter TJ, Hahn O, Guenther JM, ... ... Perou CM, et al. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial. Jama Oncology. PMID 38236590 DOI: 10.1001/jamaoncol.2023.6038 |
0.39 |
|
| 2023 |
Zagami P, Fernandez-Martinez A, Rashid NU, Hoadley KA, Spears PA, Curigliano G, Perou CM, Carey LA. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer. Jama Network Open. 6: e2348814. PMID 38117494 DOI: 10.1001/jamanetworkopen.2023.48814 |
0.642 |
|
| 2023 |
Xiang S, Zhang W, Liu S, Hoadley KA, Perou CM, Zhang K, Marron JS. PAIRWISE NONLINEAR DEPENDENCE ANALYSIS OF GENOMIC DATA. The Annals of Applied Statistics. 17: 2924-2943. PMID 38046186 DOI: 10.1214/23-aoas1745 |
0.549 |
|
| 2023 |
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley KA, Parker JS, Singh B, Campbell JD, Ballman KV, Hillman DW, Winer EP, El-Abed S, Piccart M, Di Cosimo S, Symmans WF, ... ... Perou CM, et al. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials. Nature Communications. 14: 7053. PMID 37923752 DOI: 10.1038/s41467-023-42635-2 |
0.755 |
|
| 2023 |
Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor CW, Safari K, Savage SR, Zhang B, ... ... Perou CM, et al. Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. The Journal of Clinical Investigation. PMID 37874652 DOI: 10.1172/JCI172503 |
0.474 |
|
| 2023 |
Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, ... ... Perou CM, et al. Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer. Biorxiv : the Preprint Server For Biology. PMID 37808840 DOI: 10.1101/2023.09.28.559973 |
0.473 |
|
| 2023 |
Kim H, Whitman AA, Wisniewska K, Kakati RT, García-Recio S, Calhoun BC, Franco HL, Perou CM, Spanheimer PM. Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37747807 DOI: 10.1158/1078-0432.CCR-23-1248 |
0.476 |
|
| 2023 |
Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, ... ... Perou CM, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 41: 4192-4199. PMID 37672882 DOI: 10.1200/JCO.22.02511 |
0.628 |
|
| 2023 |
Tovey H, Sipos O, Parker JS, Hoadley KA, Quist J, Kernaghan S, Kilburn L, Salgado R, Loi S, Kennedy RD, Roxanis I, Gazinska P, Pinder SE, Bliss J, Perou CM, et al. Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. OF1-OF15. PMID 37574209 DOI: 10.1158/1078-0432.CCR-23-0370 |
0.704 |
|
| 2023 |
Lim C, Hwang D, Yazdimamaghani M, Atkins HM, Hyun H, Shin Y, Ramsey JD, Rädler PD, Mott KR, Perou CM, Sokolsky-Papkov M, Kabanov AV. High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer. Nano Today. 51. PMID 37484164 DOI: 10.1016/j.nantod.2023.101884 |
0.405 |
|
| 2023 |
Jiang Z, Ju Y, Ali A, Chung PED, Skowron P, Wang DY, Shrestha M, Li H, Liu JC, Vorobieva I, Ghanbari-Azarnier R, Mwewa E, Koritzinsky M, Ben-David Y, Woodgett JR, ... Perou CM, et al. Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer. Nature Communications. 14: 4313. PMID 37463901 DOI: 10.1038/s41467-023-39935-y |
0.491 |
|
| 2023 |
Vinod N, Hwang D, Fussell SC, Owens TC, Tofade OC, Copling S, Ramsey JD, Rädler PD, Atkins HM, Livingston EE, Ashley Ezzell J, Papkov MS, Yuan H, Perou CM, Kabanov AV. Combination of Polymeric Micelle Formulation of TGFβ Receptor Inhibitors and Paclitaxel Produce Consistent Response Across Different Mouse Models of TNBC. Biorxiv : the Preprint Server For Biology. PMID 37398150 DOI: 10.1101/2023.06.14.544381 |
0.383 |
|
| 2023 |
Swarbrick A, Fernandez-Martinez A, Perou CM. Gene-Expression Profiling to Decipher Breast Cancer Inter- and Intratumor Heterogeneity. Cold Spring Harbor Perspectives in Medicine. PMID 37137498 DOI: 10.1101/cshperspect.a041320 |
0.558 |
|
| 2023 |
Waks AG, Ogayo ER, Paré L, Marín-Aguilera M, Brasó-Maristany F, Galván P, Castillo O, Martínez-Sáez O, Vivancos A, Villagrasa P, Villacampa G, Tarantino P, Desai N, Guerriero J, Metzger O, ... ... Perou CM, et al. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab. Jama Oncology. PMID 37103927 DOI: 10.1001/jamaoncol.2023.0181 |
0.599 |
|
| 2023 |
Bueno-Muiño C, Echavarría I, López-Tarruella S, Roche-Molina M, Del Monte-Millán M, Massarrah T, Jerez Y, Ayala de la Peña F, García-Sáenz JÁ, Moreno F, Rodríguez-Lescure Á, Malón-Giménez D, Ballesteros García AI, Marín-Aguilera M, Galván P, ... ... Perou CM, et al. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab. Jama Oncology. PMID 37103916 DOI: 10.1001/jamaoncol.2023.0187 |
0.626 |
|
| 2023 |
Kim H, Whitman AA, Wisniewska K, Kakati RT, Garcia-Recio S, Calhoun BC, Franco HL, Perou CM, Spanheimer PM. Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors. Biorxiv : the Preprint Server For Biology. PMID 37066379 DOI: 10.1101/2023.04.01.535159 |
0.44 |
|
| 2023 |
Howard FM, Dolezal J, Kochanny S, Khramtsova G, Vickery J, Srisuwananukorn A, Woodard A, Chen N, Nanda R, Perou CM, Olopade OI, Huo D, Pearson AT. Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. Npj Breast Cancer. 9: 25. PMID 37059742 DOI: 10.1038/s41523-023-00530-5 |
0.366 |
|
| 2023 |
McClure MB, Kogure Y, Ansari-Pour N, Saito Y, Chao HH, Shepherd J, Tabata M, Olopade OI, Wedge DC, Hoadley KA, Perou CM, Kataoka K. Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals Aneuploidy-driven Metabolic Reprogramming. Cancer Research Communications. 3: 281-296. PMID 36860655 DOI: 10.1158/2767-9764.CRC-22-0073 |
0.768 |
|
| 2023 |
Prat A, Brasó-Maristany F, Martínez-Sáez O, Sanfeliu E, Xia Y, Bellet M, Galván P, Martínez D, Pascual T, Marín-Aguilera M, Rodríguez A, Chic N, Adamo B, Paré L, Vidal M, ... ... Perou CM, et al. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nature Communications. 14: 1157. PMID 36859416 DOI: 10.1038/s41467-023-36801-9 |
0.643 |
|
| 2023 |
Price BA, Marron JS, Mose LE, Perou CM, Parker JS. Translating transcriptomic findings from cancer model systems to humans through joint dimension reduction. Communications Biology. 6: 179. PMID 36797360 DOI: 10.1038/s42003-023-04529-3 |
0.504 |
|
| 2023 |
Mueller SH, Lai AG, Valkovskaya M, Michailidou K, Bolla MK, Wang Q, Dennis J, Lush M, Abu-Ful Z, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, ... ... Perou CM, et al. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry. Genome Medicine. 15: 7. PMID 36703164 DOI: 10.1186/s13073-022-01152-5 |
0.409 |
|
| 2023 |
Fernandez-Martinez A, Pascual T, Singh B, Nuciforo P, Rashid NU, Ballman KV, Campbell JD, Hoadley KA, Spears PA, Pare L, Brasó-Maristany F, Chic N, Krop I, Partridge A, Cortés J, ... ... Perou CM, et al. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Correlative Analysis of the CALGB 40601 and PAMELA Trials. Jama Oncology. PMID 36602784 DOI: 10.1001/jamaoncol.2022.6288 |
0.669 |
|
| 2022 |
Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, ... ... Perou CM, et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer. PMID 36585450 DOI: 10.1038/s43018-022-00491-x |
0.76 |
|
| 2022 |
Brasó-Maristany F, Griguolo G, Chic N, Pascual T, Paré L, Maues J, Galván P, Dieci MV, Miglietta F, Giarratano T, Martínez-Sáez O, Marín-Aguilera M, Schettini F, Conte B, Angelats L, ... ... Perou CM, et al. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1. Journal of the National Cancer Institute. PMID 36576009 DOI: 10.1093/jnci/djac227 |
0.543 |
|
| 2022 |
Guarneri V, Bras-Maristany F, Dieci MV, Griguolo G, Par L, Mar Ín-Aguilera M, Miglietta F, Bottosso M, Giorgi CA, Blasco P, Castillo O, Galv N P, Vivancos A, Villagrasa P, Parker JS, ... Perou CM, et al. HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial. Ebiomedicine. 85: 104320. PMID 36374768 DOI: 10.1016/j.ebiom.2022.104320 |
0.636 |
|
| 2022 |
Walens A, Van Alsten SC, Olsson LT, Smith MA, Lockhart A, Gao X, Hamilton AM, Kirk EL, Love MI, Gupta GP, Perou CM, Vaziri C, Hoadley KA, Troester MA. RNA-based classification of homologous recombination deficiency in racially-diverse patients with breast cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 36129803 DOI: 10.1158/1055-9965.EPI-22-0590 |
0.6 |
|
| 2022 |
File DM, Pascual T, Deal AM, Wheless A, Perou CM, Claire Dees E, Carey LA. Clinical subtype, treatment response, and survival in De Novo and recurrent metastatic breast cancer. Breast Cancer Research and Treatment. PMID 36008651 DOI: 10.1007/s10549-022-06700-6 |
0.425 |
|
| 2022 |
Thennavan A, Garcia-Recio S, Liu S, He X, Perou CM. Molecular signatures of in situ to invasive progression for basal-like breast cancers: An integrated mouse model and human DCIS study. Npj Breast Cancer. 8: 83. PMID 35851387 DOI: 10.1038/s41523-022-00450-w |
0.478 |
|
| 2022 |
Jung AY, Ahearn TU, Behrens S, Middha P, Bolla MK, Wang Q, Arndt V, Aronson KJ, Augustinsson A, Beane Freeman LE, Becher H, Brenner H, Canzian F, Carey LA, Czene K, ... ... Perou CM, et al. Distinct reproductive risk profiles for intrinsic-like breast cancer subtypes: pooled analysis of population-based studies. Journal of the National Cancer Institute. PMID 35723569 DOI: 10.1093/jnci/djac117 |
0.417 |
|
| 2022 |
Hurson AN, Abubakar M, Hamilton AM, Conway K, Hoadley KA, Love MI, Olshan AF, Perou CM, Garcia-Closas M, Troester MA. Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases. Npj Breast Cancer. 8: 74. PMID 35701440 DOI: 10.1038/s41523-022-00437-7 |
0.668 |
|
| 2022 |
Xia Y, He X, Renshaw L, Martinez-Perez C, Kay C, Gray M, Meehan J, Parker JS, Perou CM, Carey LA, Dixon JM, Turnbull A. Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor-Positive Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35653148 DOI: 10.1158/1078-0432.CCR-21-3189 |
0.637 |
|
| 2022 |
Thennavan A, Beca F, Xia Y, Recio SG, Allison K, Collins LC, Tse GM, Chen YY, Schnitt SJ, Hoadley KA, Beck A, Perou CM. Molecular analysis of TCGA breast cancer histologic types. Cell Genomics. 1. PMID 35465400 DOI: 10.1016/j.xgen.2021.100067 |
0.675 |
|
| 2022 |
Singh S, Lee N, Pedroza DA, Bado IL, Hamor C, Zhang L, Aguirre S, Hu J, Shen Y, Xu Y, Gao Y, Zhao N, Chen SH, Wan YW, Liu Z, ... ... Perou CM, et al. Chemotherapy coupled to macrophage inhibition induces T-cell and B-cell infiltration and durable regression in triple-negative breast cancer. Cancer Research. PMID 35442423 DOI: 10.1158/0008-5472.CAN-21-3714 |
0.457 |
|
| 2022 |
Hamilton AM, Hurson AN, Olsson LT, Walens A, Nsonwu-Farley J, Kirk EL, Abdou Y, Downs-Canner SM, Serody JS, Perou CM, Calhoun BC, Troester MA, Hoadley KA. The landscape of immune microenvironments in racially-diverse breast cancer patients. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35437570 DOI: 10.1158/1055-9965.EPI-21-1312 |
0.636 |
|
| 2022 |
Wang X, Kapoor PM, Auer PL, Dennis J, Dunning AM, Wang Q, Lush M, Michailidou K, Bolla MK, Aronson KJ, Murphy RA, Brooks-Wilson A, Lee DG, Cordina-Duverger E, Guénel P, ... ... Perou CM, et al. Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports. 12: 6199. PMID 35418701 DOI: 10.1038/s41598-022-10121-2 |
0.343 |
|
| 2022 |
Bhatia S, Kramer M, Russo S, Naik P, Arun G, Brophy K, Andrews P, Fan C, Perou CM, Preall J, Ha T, Plenker D, Tuveson DA, Rishi A, Wilkinson JE, et al. Patient-derived triple-negative breast cancer organoids provide robust model systems that recapitulate tumor-intrinsic characteristics. Cancer Research. PMID 35180770 DOI: 10.1158/0008-5472.CAN-21-2807 |
0.504 |
|
| 2022 |
Anders CK, Woodcock MG, Van Swearingen AED, Moore DT, Sambade MJ, Laurie S, Robeson A, Kolupaev O, Cuaboy LA, Garrett AL, McKinnon K, Cowens K, Bortone D, Calhoun BC, Wilkinson AD, ... ... Perou C, et al. Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer. Journal For Immunotherapy of Cancer. 10. PMID 35121644 DOI: 10.1136/jitc-2021-003427 |
0.363 |
|
| 2022 |
Shepherd JH, Ballman K, Polley MC, Campbell JD, Fan C, Selitsky S, Fernandez-Martinez A, Parker JS, Hoadley KA, Hu Z, Li Y, Soloway MG, Spears PA, Singh B, Tolaney SM, ... ... Perou CM, et al. CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2101506. PMID 35044810 DOI: 10.1200/JCO.21.01506 |
0.688 |
|
| 2022 |
Dennis J, Tyrer JP, Walker LC, Michailidou K, Dorling L, Bolla MK, Wang Q, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Freeman LEB, Beckmann MW, ... ... Perou CM, et al. Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology. 5: 65. PMID 35042965 DOI: 10.1038/s42003-021-02990-6 |
0.417 |
|
| 2022 |
Prat A, Guarneri V, Pascual T, Brasó-Maristany F, Sanfeliu E, Paré L, Schettini F, Martínez D, Jares P, Griguolo G, Dieci MV, Cortés J, Llombart-Cussac A, Conte B, Marín-Aguilera M, ... ... Perou CM, et al. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer. Ebiomedicine. 75: 103801. PMID 34990895 DOI: 10.1016/j.ebiom.2021.103801 |
0.595 |
|
| 2021 |
Carmichael I, Calhoun BC, Hoadley KA, Troester MA, Geradts J, Couture HD, Olsson L, Perou CM, Niethammer M, Hannig J, Marron JS. JOINT AND INDIVIDUAL ANALYSIS OF BREAST CANCER HISTOLOGIC IMAGES AND GENOMIC COVARIATES. The Annals of Applied Statistics. 15: 1697-1722. PMID 35432688 DOI: 10.1214/20-aoas1433 |
0.632 |
|
| 2021 |
Gao Y, Kabotyanski EB, Shepherd JH, Villegas E, Acosta D, Hamor C, Sun T, Montmeyor-Garcia C, He X, Dobrolecki LE, Westbrook TF, Lewis MT, Hilsenbeck SG, Zhang XH, Perou CM, et al. Tumor suppressor PLK2 may serve as a biomarker in triple-negative breast cancer for improved response to PLK1 therapeutics. Cancer Research Communications. 1: 178-193. PMID 35156101 DOI: 10.1158/2767-9764.crc-21-0106 |
0.457 |
|
| 2021 |
Liao C, Glodowski CR, Fan C, Liu J, Mott KR, Kaushik A, Vu H, Locasale JW, McBrayer SK, DeBerardinis RJ, Perou CM, Zhang Q. Integrated Metabolic Profiling and Transcriptional Analysis Reveals Therapeutic Modalities for Targeting Rapidly Proliferating Breast Cancers. Cancer Research. PMID 34911787 DOI: 10.1158/0008-5472.CAN-21-2745 |
0.484 |
|
| 2021 |
Regner MJ, Wisniewska K, Garcia-Recio S, Thennavan A, Mendez-Giraldez R, Malladi VS, Hawkins G, Parker JS, Perou CM, Bae-Jump VL, Franco HL. A multi-omic single-cell landscape of human gynecologic malignancies. Molecular Cell. 81: 4924-4941.e10. PMID 34739872 DOI: 10.1016/j.molcel.2021.10.013 |
0.554 |
|
| 2021 |
Hurson AN, Abubakar M, Hamilton AM, Conway K, Hoadley KA, Love MI, Olshan AF, Perou CM, Garcia-Closas M, Troester MA. TP53 Pathway Function, Estrogen Receptor Status, and Breast Cancer Risk Factors in the Carolina Breast Cancer Study. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 34737209 DOI: 10.1158/1055-9965.EPI-21-0661 |
0.649 |
|
| 2021 |
Patel A, Garcia-Closas M, Olshan AF, Perou CM, Troester MA, Love MI, Bhattacharya A. Gene level germline contributions to clinical risk of recurrence scores in Black and White breast cancer patients. Cancer Research. PMID 34711612 DOI: 10.1158/0008-5472.CAN-21-1207 |
0.402 |
|
| 2021 |
Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, Thennavan A, Wang C, Torpy JR, Bartonicek N, Wang T, Larsson L, Kaczorowski D, Weisenfeld NI, Uytingco CR, ... ... Perou CM, et al. A single-cell and spatially resolved atlas of human breast cancers. Nature Genetics. 53: 1334-1347. PMID 34493872 DOI: 10.1038/s41588-021-00911-1 |
0.442 |
|
| 2021 |
Schachter NF, Adams JR, Skowron P, Kozma KJ, Lee CA, Raghuram N, Yang J, Loch AJ, Wang W, Kucharczuk A, Wright KL, Quintana RM, An Y, Dotzko D, Gorman JL, ... ... Perou CM, et al. Single allele loss-of-function mutations select and sculpt conditional cooperative networks in breast cancer. Nature Communications. 12: 5238. PMID 34475389 DOI: 10.1038/s41467-021-25467-w |
0.418 |
|
| 2021 |
Chic N, Schettini F, Brasó-Maristany F, Sanfeliu E, Adamo B, Vidal M, Martínez D, Galván P, González-Farré B, Cortés J, Gavilá J, Saura C, Oliveira M, Pernas S, Martínez-Sáez O, ... ... Perou CM, et al. Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT. Ebiomedicine. 69: 103451. PMID 34161883 DOI: 10.1016/j.ebiom.2021.103451 |
0.433 |
|
| 2021 |
Rädler PD, Wehde BL, Triplett AA, Shrestha H, Shepherd JH, Pfefferle AD, Rui H, Cardiff RD, Perou CM, Wagner KU. Highly metastatic claudin-low mammary cancers can originate from luminal epithelial cells. Nature Communications. 12: 3742. PMID 34145248 DOI: 10.1038/s41467-021-23957-5 |
0.438 |
|
| 2021 |
He Y, Wang L, Wei T, Xiao YT, Sheng H, Su H, Hollern DP, Zhang X, Ma J, Wen S, Xie H, Yan Y, Pan Y, Hou X, Tang X, ... ... Perou CM, et al. FOXA1 overexpression suppresses interferon signaling and immune response in cancer. The Journal of Clinical Investigation. PMID 34101624 DOI: 10.1172/JCI147025 |
0.423 |
|
| 2021 |
Angus SP, Stuhlmiller TJ, Mehta G, Bevill SM, Goulet DR, Olivares-Quintero JF, East MP, Tanioka M, Zawistowski JS, Singh D, Sciaky N, Chen X, He X, Rashid NU, Chollet-Hinton L, ... ... Perou CM, et al. FOXA1 and adaptive response determinants to HER2 targeted therapy in TBCRC 036. Npj Breast Cancer. 7: 51. PMID 33980863 DOI: 10.1038/s41523-021-00258-0 |
0.572 |
|
| 2021 |
Morton LM, Karyadi DM, Stewart C, Bogdanova TI, Dawson ET, Steinberg MK, Dai J, Hartley SW, Schonfeld SJ, Sampson JN, Maruvka Y, Kapoor V, Ramsden DA, Carvajal-Garcia J, Perou CM, et al. Radiation-related genomic profile of papillary thyroid cancer after the Chernobyl accident. Science (New York, N.Y.). PMID 33888599 DOI: 10.1126/science.abg2538 |
0.412 |
|
| 2021 |
Pascual T, Fernandez-Martinez A, Tanioka M, Dieci MV, Pernas S, Gavilá J, Guarneri V, Cortés J, Villagrasa P, Chic N, Vidal M, Adamo B, Muñoz M, Griguolo G, Llombart-Cussac A, ... ... Perou CM, et al. Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33632929 DOI: 10.1158/1078-0432.CCR-20-4102 |
0.397 |
|
| 2021 |
Walsh T, Gulsuner S, Lee MK, Troester MA, Olshan AF, Earp HS, Perou CM, King MC. Inherited predisposition to breast cancer in the Carolina Breast Cancer Study. Npj Breast Cancer. 7: 6. PMID 33479248 DOI: 10.1038/s41523-020-00214-4 |
0.507 |
|
| 2021 |
Bai F, Liu S, Liu X, Hollern DP, Scott A, Wang C, Zhang L, Fan C, Fu L, Perou CM, Zhu WG, Pei XH. PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors. Breast Cancer Research : Bcr. 23: 10. PMID 33478572 DOI: 10.1186/s13058-021-01387-x |
0.425 |
|
| 2021 |
Benefield HC, Reeder-Hayes KE, Nichols HB, Calhoun BC, Love MI, Kirk EL, Geradts J, Hoadley KA, Cole SR, Earp HS, Olshan AF, Carey LA, Perou CM, Troester MA. Outcomes of Hormone-Receptor Positive, HER2-Negative Breast Cancers by Race and Tumor Biological Features. Jnci Cancer Spectrum. 5: pkaa072. PMID 33442657 DOI: 10.1093/jncics/pkaa072 |
0.621 |
|
| 2020 |
Prat A, Guarneri V, Paré L, Griguolo G, Pascual T, Dieci MV, Chic N, González-Farré B, Frassoldati A, Sanfeliu E, Cejalvo JM, Muñoz M, Bisagni G, Brasó-Maristany F, Urso L, ... ... Perou CM, et al. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. The Lancet. Oncology. 21: 1455-1464. PMID 33152285 DOI: 10.1016/S1470-2045(20)30450-2 |
0.603 |
|
| 2020 |
Fernandez-Martinez A, Krop IE, Hillman DW, Polley MY, Parker JS, Huebner L, Hoadley KA, Shepherd J, Tolaney S, Henry NL, Dang C, Harris L, Berry D, Hahn O, Hudis C, ... ... Perou CM, et al. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2001276. PMID 33095682 DOI: 10.1200/JCO.20.01276 |
0.685 |
|
| 2020 |
Deng J, Thennavan A, Shah S, Bagdatlioglu E, Klar N, Heguy A, Marier C, Meyn P, Zhang Y, Labbe K, Almonte C, Krogsgaard M, Perou CM, Wong KK, Adams S. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment. Breast Cancer Research and Treatment. PMID 32949350 DOI: 10.1007/S10549-020-05936-4 |
0.45 |
|
| 2020 |
Luckett DJ, Laber EB, El-Kamary SS, Fan C, Jhaveri R, Perou CM, Shebl FM, Kosorok MR. Receiver operating characteristic curves and confidence bands for support vector machines. Biometrics. PMID 32865820 DOI: 10.1111/Biom.13365 |
0.322 |
|
| 2020 |
Mayer EL, Abramson V, Jankowitz R, Falkson C, Marcom PK, Traina T, Carey L, Rimawi M, Specht J, Miller K, Stearns V, Tung N, Perou C, Richardson AL, Componeschi K, et al. TBCRC 030: A phase II study of preoperative cisplatin vs. paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) biomarker. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32798689 DOI: 10.1016/J.Annonc.2020.08.2064 |
0.513 |
|
| 2020 |
Crosby EJ, Acharya CR, Haddad AF, Rabiola CA, Lei G, Wei JP, Yang XY, Wang T, Liu CX, Wagner KU, Muller WJ, Chodosh LA, Broadwater G, Hyslop T, Shepherd JH, ... ... Perou CM, et al. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32732224 DOI: 10.1158/1078-0432.Ccr-20-0389 |
0.457 |
|
| 2020 |
Liao C, Zhang Y, Fan C, Herring LE, Liu J, Locasale JW, Takada M, Zhou J, Zurlo G, Hu L, Simon JM, Ptacek TS, Andrianov VG, Loza E, Peng Y, ... ... Perou CM, et al. Identification of BBOX1 as a Therapeutic Target in Triple-Negative Breast Cancer. Cancer Discovery. PMID 32690540 DOI: 10.1158/2159-8290.Cd-20-0288 |
0.475 |
|
| 2020 |
Lundberg A, Lindström LS, Parker JS, Löverli E, Perou CM, Bergh J, Tobin NP. A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels. Oncogene. PMID 32581248 DOI: 10.1038/S41388-020-1367-4 |
0.549 |
|
| 2020 |
Garcia-Recio S, Thennavan A, East MP, Parker JS, Cejalvo JM, Garay JP, Hollern DP, He X, Mott KR, Galván P, Fan C, Selitsky SR, Coffey AR, Marron D, Brasó-Maristany F, ... ... Perou CM, et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. The Journal of Clinical Investigation. PMID 32573490 DOI: 10.1172/Jci130323 |
0.698 |
|
| 2020 |
Kapoor PM, Mavaddat N, Choudhury PP, Wilcox AN, Lindström S, Behrens S, Michailidou K, Dennis J, Bolla MK, Wang Q, Jung A, Abu-Ful Z, Ahearn T, Andrulis IL, Anton-Culver H, ... ... Perou CM, et al. Combined associations of a polygenic risk score and classical risk factors with breast cancer risk. Journal of the National Cancer Institute. PMID 32359158 DOI: 10.1093/Jnci/Djaa056 |
0.434 |
|
| 2020 |
Bhattacharya A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI. A framework for transcriptome-wide association studies in breast cancer in diverse study populations. Genome Biology. 21: 42. PMID 32079541 DOI: 10.1186/S13059-020-1942-6 |
0.538 |
|
| 2020 |
Schettini F, Pascual T, Conte B, Chic N, Brasó-Maristany F, Galván P, Martínez O, Adamo B, Vidal M, Muñoz M, Fernández-Martinez A, Rognoni C, Griguolo G, Guarneri V, Conte PF, ... ... Perou CM, et al. HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treatment Reviews. 84: 101965. PMID 32000054 DOI: 10.1016/J.Ctrv.2020.101965 |
0.522 |
|
| 2020 |
Selitsky SR, Marron D, Hollern D, Mose LE, Hoadley KA, Jones C, Parker JS, Dittmer DP, Perou CM. Virus expression detection reveals RNA-sequencing contamination in TCGA. Bmc Genomics. 21: 79. PMID 31992194 DOI: 10.1186/S12864-020-6483-6 |
0.634 |
|
| 2020 |
Satpathy S, Jaehnig EJ, Krug K, Kim BJ, Saltzman AB, Chan DW, Holloway KR, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar SV, ... ... Perou CM, et al. Microscaled proteogenomic methods for precision oncology. Nature Communications. 11: 532. PMID 31988290 DOI: 10.1038/S41467-020-14381-2 |
0.463 |
|
| 2020 |
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902309. PMID 31928404 DOI: 10.1200/Jco.19.02309 |
0.481 |
|
| 2020 |
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Archives of Pathology & Laboratory Medicine. PMID 31928354 DOI: 10.5858/Arpa.2019-0904-Sa |
0.437 |
|
| 2020 |
Dong M, Thennavan A, Urrutia E, Li Y, Perou CM, Zou F, Jiang Y. SCDC: bulk gene expression deconvolution by multiple single-cell RNA sequencing references. Briefings in Bioinformatics. PMID 31925417 DOI: 10.1093/Bib/Bbz166 |
0.317 |
|
| 2020 |
Tovey H, Parker JS, Hoadley KA, Kennedy RD, Sipos O, Kilburn L, Kernaghan S, Gazinska P, Haider S, Pinder SE, Bliss J, Perou CM, Grigoriadis A, Tutt A, Cheang MCU. Evaluation of DNA repair biology signatures to predict specific carboplatin (C) versus docetaxel (D) benefit in advanced triple-negative breast cancer (aTNBC). Journal of Clinical Oncology. 38: 1074-1074. DOI: 10.1200/Jco.2020.38.15_Suppl.1074 |
0.695 |
|
| 2020 |
Earp HS, Olshan AF, Carey LA, Perou CM, Troester MA, Benefield HC, Reeder-Hayes KE, Nichols HB, Calhoun BC, Love MI, Sun X, Kirk EL, Geradts J, Hoadley KA, Cole SR. Abstract C045: Outcomes of hormone-receptor positive, HER2-negative breast cancers by race and tumor biologic features Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-C045 |
0.692 |
|
| 2020 |
Bhattacharya A, García-Closas M, Olshan AF, Perou CM, Troester MA, Love MI. Abstract B065: A framework for transcriptome-wide association studies in breast cancer in diverse study populations Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-B065 |
0.486 |
|
| 2020 |
Thennavan A, He X, Perou CM. Abstract PD6-9: Molecular signatures of DCIS to invasive progression for basal-like breast cancers: An integrated mouse model and human tumor study Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-Pd6-9 |
0.504 |
|
| 2020 |
Turnbull AK, Xa Y, Martinez-Perez C, Oikonomidou O, Meehan J, Gray M, Carey LA, Perou CM, Dixon JM. Abstract P6-04-03: In-depth genomic analysis of acquired resistance to multiple sequential lines of endocrine therapy in breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-04-03 |
0.402 |
|
| 2020 |
Gao Y, Kabotyanski E, Acosta D, Villegas E, Westbrook TF, Perou CM, Rosen JM. Abstract P4-08-01: Tumor suppressor PLK2 may serve as a biomarker in triple negative breast cancer for combinational therapy of PLK1 inhibitors with the standard-of-care chemotherapy Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-08-01 |
0.576 |
|
| 2020 |
Schuster EF, Zabalgo L, Perou CM, Dowsett M. Abstract P4-06-02: Multi-parameter FACS sorting identifies higher mutational burden in aromatase inhibitor resistant subclones in estrogen positive breast cancer at diagnosis Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P4-06-02 |
0.473 |
|
| 2020 |
Xia Y, Fan C, Hoadley KA, Parker JS, Perou CM. Abstract P4-05-12: Genetic determinants of the molecular portraits of epithelial cancers Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-05-12 |
0.768 |
|
| 2020 |
Hoadley KA, Powell BC, Kanavy D, Marron D, Mose LE, Hyslop T, Berry DA, Hahn O, Tolaney SM, Sikov WM, Perou CM, Carey LA. Abstract P4-05-03: Mutational analysis of triple-negative breast cancer (TNBC): CALGB 40603 (Alliance) Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P4-05-03 |
0.635 |
|
| 2020 |
King TA, Liu MC, McClure MB, Hinoue T, Kelly BJ, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Rezk S, Garrett AL, Balko JM, Parker JS, Park BH, ... ... Perou CM, et al. Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs3-08 |
0.788 |
|
| 2020 |
Satpathy S, Jaehnig E, Karsten K, Kim B, Saltzman A, Chan D, Holloway K, Anurag M, Huang C, Singh P, Gao A, Namai N, Dou Y, Wen B, Vasaikar S, ... ... Perou C, et al. Abstract GS2-05: Microscaled proteogenomic methods for precision oncology Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs2-05 |
0.523 |
|
| 2020 |
Wahl G, Ma Z, Chung C, Dravis C, Spike B, Giraddi R, Balcioglu O, Fan C, Hagos B, Heinz R, Herrera-Valdez J, Hou X, Hwang J, Lasken R, Luna G, ... ... Perou C, et al. Abstract ES10-2: Understanding breast cancer using a developmental perspective Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Es10-2 |
0.52 |
|
| 2020 |
Crosby EJ, Acharya C, Rabiola C, Muller WJ, Chodosh LA, Broadwater G, Shepherd J, Hollern D, He X, Perou CM, Ashby BK, Vincent BG, Morse MA, Lyerly HK, Hartman ZC. Abstract 904: Stimulation and expansion of oncogene-reactive tumor infiltrating T cells through combined Ad-HER2Δ16 vaccination and anti-PD1 enable anti-tumor responses against established HER2 BC Immunology. DOI: 10.1158/1538-7445.Am2020-904 |
0.332 |
|
| 2020 |
Pascual T, Fernandez-Martinez A, Tanioka M, Dieci MV, Simon SP, Gregori JG, Guarneri V, Cortés J, Villagrasa P, Vidal MJ, Adamo B, Muñoz M, Griguolo G, Cussac AL, Oliveira M, ... ... Perou CM, et al. 4P Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC) Annals of Oncology. 31. DOI: 10.1016/J.Annonc.2020.03.140 |
0.498 |
|
| 2019 |
Xia Y, Fan C, Hoadley KA, Parker JS, Perou CM. Genetic determinants of the molecular portraits of epithelial cancers. Nature Communications. 10: 5666. PMID 31827079 DOI: 10.1038/S41467-019-13588-2 |
0.763 |
|
| 2019 |
Benefield HC, Allott EH, Reeder-Hayes KE, Perou CM, Carey LA, Geradts J, Sun X, Calhoun BC, Troester MA. Borderline estrogen receptor-positive breast cancers in black and white women. Journal of the National Cancer Institute. PMID 31742342 DOI: 10.1093/Jnci/Djz206 |
0.498 |
|
| 2019 |
Hollern DP, Xu N, Thennavan A, Glodowski C, Garcia-Recio S, Mott KR, He X, Garay JP, Carey-Ewend K, Marron D, Ford J, Liu S, Vick SC, Martin M, Parker JS, ... ... Perou CM, et al. B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer. Cell. 179: 1191-1206.e21. PMID 31730857 DOI: 10.1016/J.Cell.2019.10.028 |
0.621 |
|
| 2019 |
Zurlo G, Liu X, Takada M, Fan C, Simon JM, Ptacek TS, Rodriguez J, von Kriegsheim A, Liu J, Locasale JW, Robinson A, Zhang J, Holler JM, Kim B, Zikánová M, ... ... Perou CM, et al. Prolyl hydroxylase substrate adenylosuccinate lyase is an oncogenic driver in triple negative breast cancer. Nature Communications. 10: 5177. PMID 31729379 DOI: 10.1038/S41467-019-13168-4 |
0.526 |
|
| 2019 |
Allott EH, Shan Y, Chen M, Sun X, Garcia-Recio S, Kirk EL, Olshan AF, Geradts J, Earp HS, Carey LA, Perou CM, Pfeiffer RM, Anderson WF, Troester MA. Bimodal age distribution at diagnosis in breast cancer persists across molecular and genomic classifications. Breast Cancer Research and Treatment. PMID 31535320 DOI: 10.1007/S10549-019-05442-2 |
0.495 |
|
| 2019 |
Kim SJ, Garcia-Recio S, Creighton CJ, Perou CM, Rosen JM. Alterations in Wnt- and/or STAT3 signaling pathways and the immune microenvironment during metastatic progression. Oncogene. PMID 31289359 DOI: 10.1038/S41388-019-0852-0 |
0.44 |
|
| 2019 |
Pfefferle AD, Darr DB, Calhoun BC, Mott KR, Rosen JM, Perou CM. The MMTV-Wnt1 murine model produces two phenotypically distinct subtypes of mammary tumors with unique therapeutic responses to an EGFR inhibitor. Disease Models & Mechanisms. PMID 31213486 DOI: 10.1242/Dmm.037192 |
0.474 |
|
| 2019 |
Picornell AC, Echavarria I, Alvarez E, López-Tarruella S, Jerez Y, Hoadley K, Parker JS, Del Monte-Millán M, Ramos-Medina R, Gayarre J, Ocaña I, Cebollero M, Massarrah T, Moreno F, García Saenz JA, ... ... Perou CM, et al. Breast cancer PAM50 signature: correlation and concordance between RNA-Seq and digital multiplexed gene expression technologies in a triple negative breast cancer series. Bmc Genomics. 20: 452. PMID 31159741 DOI: 10.1186/S12864-019-5849-0 |
0.764 |
|
| 2019 |
Waks AG, Stover DG, Guerriero JL, Dillon DA, Barry WT, Gjini E, Hartl CA, Lo WT, Savoie J, Brock J, Wesolowski R, Li Z, Damicis A, Philips AV, Wu Y, ... ... Perou CM, et al. The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31061067 DOI: 10.1158/1078-0432.Ccr-19-0173 |
0.709 |
|
| 2019 |
Jiang Y, Zhang Y, Leung JY, Fan C, Popov KI, Su S, Qian J, Wang X, Holtzhausen A, Ubil E, Xiang Y, Davis I, Dokholyan NV, Wu G, Perou CM, et al. MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression. Nature Communications. 10: 1515. PMID 30944303 DOI: 10.1038/S41467-019-09233-7 |
0.301 |
|
| 2019 |
Wong KY, Fan C, Tanioka M, Parker JS, Nobel AB, Zeng D, Lin DY, Perou CM. I-Boost: an integrative boosting approach for predicting survival time with multiple genomics platforms. Genome Biology. 20: 52. PMID 30845957 DOI: 10.1186/S13059-019-1640-4 |
0.535 |
|
| 2019 |
Alzubi MA, Turner TH, Olex AL, Sohal SS, Tobin NP, Recio SG, Bergh J, Hatschek T, Parker JS, Sartorius CA, Perou CM, Dozmorov MG, Harrell JC. Separation of breast cancer and organ microenvironment transcriptomes in metastases. Breast Cancer Research : Bcr. 21: 36. PMID 30841919 DOI: 10.1186/S13058-019-1123-2 |
0.59 |
|
| 2019 |
Lundberg A, Lindström LS, Li J, Harrell JC, Darai-Ramqvist E, Sifakis EG, Foukakis T, Perou CM, Czene K, Bergh J, Tobin NP. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. Breast Cancer Research : Bcr. 21: 34. PMID 30819233 DOI: 10.1186/S13058-019-1121-4 |
0.44 |
|
| 2019 |
Mose LE, Perou CM, Parker JS. Improved Indel Detection in DNA and RNA via Realignment with ABRA2. Bioinformatics (Oxford, England). PMID 30649250 DOI: 10.1093/Bioinformatics/Btz033 |
0.497 |
|
| 2019 |
Williams LA, Hoadley KA, Nichols HB, Geradts J, Perou CM, Love MI, Olshan AF, Troester MA. Differences in race, molecular and tumor characteristics among women diagnosed with invasive ductal and lobular breast carcinomas. Cancer Causes & Control : Ccc. PMID 30617775 DOI: 10.1007/S10552-018-1121-1 |
0.718 |
|
| 2019 |
Sikov WM, Polley M, Twohy E, Perou CM, Singh B, Berry DA, Tolaney SM, Somlo G, Port ER, Ma CX, Kuzma CS, Mamounas EP, Golshan M, Bellon JR, Collyar DE, et al. CALGB (Alliance) 40603: Long-term outcomes (LTOs) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) and bevacizumab (Bev) in triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 37: 591-591. DOI: 10.1200/Jco.2019.37.15_Suppl.591 |
0.412 |
|
| 2019 |
Fernandez-Martinez A, Tanioka M, Fan C, Parker JS, Hoadley KA, Krop IE, Cortes J, Llombart Cussac A, Nuciforo P, Galván P, Pascual T, Partridge AH, Prat A, Carey LA, Perou CM. Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials. Journal of Clinical Oncology. 37: 571-571. DOI: 10.1200/Jco.2019.37.15_Suppl.571 |
0.723 |
|
| 2019 |
Mayer EL, Abramson VG, Jankowitz RC, Falkson CI, Marcom PK, Traina TA, Carey LA, Rimawi MF, Specht JM, Miller K, Stearns V, Perou CM, Richardson AL, Tung NM, Barry WT, et al. TBCRC 030: A randomized phase II study of preoperative cisplatin versus paclitaxel in TNBC—Evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology. 37: 507-507. DOI: 10.1200/Jco.2019.37.15_Suppl.507 |
0.306 |
|
| 2019 |
Mayhew G, Shibata Y, Uronis JM, Hayward MC, Rose TL, Kim WY, Perou CM, Lai-Goldman M, Milburn MV. RNAseq and DNA whole-exome sequence analysis reveal novel response signatures to IO treatment in muscle invasive bladder cancer (MIBC) patients. Journal of Clinical Oncology. 37: 4558-4558. DOI: 10.1200/Jco.2019.37.15_Suppl.4558 |
0.388 |
|
| 2019 |
Shepherd J, Perou C. Abstract B185: Epithelial cancer cell-expressed genes contribute to clinically relevant immune-based classifications of breast cancer Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-B185 |
0.49 |
|
| 2019 |
Hollern D, Xu N, Mott K, He X, Carey-Ewend K, Marron D, Ford J, Parker J, Vincent B, Serody J, Perou C. Abstract GS1-05: Apobec3 induced mutagenesis sensitizes murine models of triple negative breast cancer to immunotherapy by activating B-cells and CD4+ T-cells Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Gs1-05 |
0.637 |
|
| 2019 |
Li S, Mendez-Giraldez R, Garay JP, Wisniewska K, Tubbs CA, Perou CM, Franco HL. Abstract 4496: Cytokine-induced post-translational modifications of FOXA1 affect enhancer selection and estrogen signaling in breast cancer cells Cancer Research. 79: 4496-4496. DOI: 10.1158/1538-7445.Sabcs18-4496 |
0.49 |
|
| 2019 |
Harmeyer K, Deng J, Shah S, Bagdatlioglu E, Ahsan A, Reid C, Thennavan A, Perou C, Wong K, Pass H. Abstract 4563: Profiling the tumor immune microenvironment of adenocarcinoma and squamous cell NSCLC Cancer Research. 79: 4563-4563. DOI: 10.1158/1538-7445.Am2019-4563 |
0.389 |
|
| 2019 |
Deng J, Thennavan A, Pan Y, Dolgalev I, Chen T, Silver H, Harris M, Pyon V, Li F, Lee C, Tsirigos A, Rothenberg E, Perou CM, Wong K. Abstract 3223: Overcome LKB1 mutated cancer resistance to anti-PD1 treatment Cancer Research. 79: 3223-3223. DOI: 10.1158/1538-7445.Am2019-3223 |
0.422 |
|
| 2019 |
Evans K, Moulder S, Yuca E, Scott S, Arango NP, Shariati M, Vellano CP, Saridogan T, Zheng X, Gonzalez-Angulo AM, Zhao M, Su X, Tapia C, Chen K, Akcakanat A, ... Perou CM, et al. Abstract C016: Oxidative phosphorylation is a metabolic vulnerability in chemotherapy resistant triple negative breast cancer Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C016 |
0.501 |
|
| 2019 |
Vincent B, Sambade M, Chai S, Siegel M, Cuaboy L, Holye A, Parker J, Perou C, Anders C. THER-06. GENOMIC AND IMMUNE CHARACTERIZATION OF TRIPLE NEGATIVE BREAST CANCER BRAIN METASTASES Neuro-Oncology Advances. 1: i11-i12. DOI: 10.1093/NOAJNL/VDZ014.049 |
0.592 |
|
| 2019 |
Schettini F, Pascual T, Chic N, Conte B, Martínez O, Adamo B, Vidal M, Muñoz M, Fernández-Martínez A, Griguolo G, Guarneri V, Conte PF, Placido SD, Carey L, Perou CM, et al. PAM50 HER2-enriched subtype and pathological complete response in HER2-positive early breast cancer: A meta-analysis Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz240.072 |
0.496 |
|
| 2019 |
Fernandez-Martinez A, Tanioka M, Fan C, Parker JS, Hoadley KA, Krop I, Partridge A, Carey L, Perou CM. Predictive and prognostic value of B-cell gene-expression signatures and B-cell receptor (BCR) repertoire in HER2+ breast cancer : A correlative analysis of the CALGB 40601 clinical trial (Alliance) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz240 |
0.763 |
|
| 2018 |
Bianchini G, Parker J, Carey L, Perou CM, Sica L, Prat A, Pieńkowski T, Im YH, Bianchi GV, Ling-Ming T, Liu MC, Lluch A, Semiglazov V, de la Haba-Rodriguez J, Oh DY, et al. Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii61. PMID 32137631 DOI: 10.1093/Annonc/Mdy270.187 |
0.461 |
|
| 2018 |
Matsunuma R, Chan DW, Kim BJ, Singh P, Han A, Saltzman AB, Cheng C, Lei JT, Wang J, Roberto da Silva L, Sahin E, Leng M, Fan C, Perou CM, Malovannaya A, et al. DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proceedings of the National Academy of Sciences of the United States of America. PMID 30498031 DOI: 10.1073/Pnas.1810598115 |
0.53 |
|
| 2018 |
Tanioka M, Mott KR, Hollern DP, Fan C, Darr DB, Perou CM. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Medicine. 10: 86. PMID 30497520 DOI: 10.1186/S13073-018-0597-3 |
0.462 |
|
| 2018 |
Hollern DP, Contreras CM, Dance-Barnes S, Silva GO, Pfefferle AD, Xiong J, Darr DB, Usary J, Mott KR, Perou CM. A mouse model featuring tissue-specific deletion of p53 and Brca1 gives rise to mammary tumors with genomic and transcriptomic similarities to human basal-like breast cancer. Breast Cancer Research and Treatment. PMID 30484104 DOI: 10.1007/S10549-018-5061-Y |
0.562 |
|
| 2018 |
Thomas A, Routh ED, Pullikuth A, Jin G, Su J, Chou JW, Hoadley KA, Print C, Knowlton N, Black MA, Demaria S, Wang E, Bedognetti D, Jones WD, Mehta GA, ... ... Perou CM, et al. Tumor mutational burden is a determinant of immune-mediated survival in breast cancer. Oncoimmunology. 7: e1490854. PMID 30386679 DOI: 10.1080/2162402X.2018.1490854 |
0.709 |
|
| 2018 |
An Y, Adams JR, Hollern DP, Zhao A, Chang SG, Gams MS, Chung PED, He X, Jangra R, Shah JS, Yang J, Beck LA, Raghuram N, Kozma KJ, Loch AJ, ... ... Perou CM, et al. Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast. Cell Reports. 25: 702-714.e6. PMID 30332649 DOI: 10.1016/J.Celrep.2018.09.056 |
0.451 |
|
| 2018 |
Couture HD, Williams LA, Geradts J, Nyante SJ, Butler EN, Marron JS, Perou CM, Troester MA, Niethammer M. Image analysis with deep learning to predict breast cancer grade, ER status, histologic subtype, and intrinsic subtype. Npj Breast Cancer. 4: 30. PMID 30182055 DOI: 10.1038/s41523-018-0079-1 |
0.358 |
|
| 2018 |
Giraddi RR, Chung CY, Heinz RE, Balcioglu O, Novotny M, Trejo CL, Dravis C, Hagos BM, Mehrabad EM, Rodewald LW, Hwang JY, Fan C, Lasken R, Varley KE, Perou CM, et al. Single-Cell Transcriptomes Distinguish Stem Cell State Changes and Lineage Specification Programs in Early Mammary Gland Development. Cell Reports. 24: 1653-1666.e7. PMID 30089273 DOI: 10.1016/J.Celrep.2018.07.025 |
0.401 |
|
| 2018 |
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, Anurag M, Singh P, He X, Kosaka Y, Matsunuma R, Crowder R, Hoog J, Phommaly C, Goncalves R, ... ... Perou CM, et al. Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Reports. 24: 1434-1444.e7. PMID 30089255 DOI: 10.1016/J.Celrep.2018.07.009 |
0.649 |
|
| 2018 |
Sharma P, López-Tarruella S, Garcia-Saenz JA, Khan QJ, Gomez H, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, Palomero MI, ... ... Perou CM, et al. Pathological response and survival in triple-negative breast cancer following neoadjuvant carboplatin plus docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30061361 DOI: 10.1158/1078-0432.Ccr-18-0585 |
0.408 |
|
| 2018 |
Tanioka M, Fan C, Parker JS, Hoadley KA, Hu Z, Li Y, Hyslop TM, Pitcher BN, Soloway MG, Spears PA, Henry NL, Tolaney S, Dang CT, Krop I, Harris LN, ... ... Perou CM, et al. Integrated analysis of RNA and DNA from a phase III trial of trastuzumab-based neoadjuvant chemotherapy identifies response predictors in HER2-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30037817 DOI: 10.1158/1078-0432.Ccr-17-3431 |
0.736 |
|
| 2018 |
Zhang J, Wu T, Simon J, Takada M, Saito R, Fan C, Liu XD, Jonasch E, Xie L, Chen X, Yao X, Teh BT, Tan P, Zheng X, Li M, ... ... Perou CM, et al. VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. Science (New York, N.Y.). 361: 290-295. PMID 30026228 DOI: 10.1126/Science.Aap8411 |
0.515 |
|
| 2018 |
Desai NV, Torous V, Parker J, Auman JT, Rosson GB, Cruz C, Perou CM, Schnitt SJ, Tung N. Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay. Breast Cancer Research : Bcr. 20: 75. PMID 29996866 DOI: 10.1186/S13058-018-1005-Z |
0.634 |
|
| 2018 |
Williams LA, Butler EN, Sun X, Allott EH, Cohen SM, Fuller AM, Hoadley KA, Perou CM, Geradts J, Olshan AF, Troester MA. TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases. Npj Breast Cancer. 4: 13. PMID 29951581 DOI: 10.1038/s41523-018-0067-5 |
0.646 |
|
| 2018 |
Cejalvo JM, Pascual T, Fernández-Martínez A, Brasó-Maristany F, Gomis RR, Perou CM, Muñoz M, Prat A. Clinical implications of the non-luminal intrinsic subtypes in hormone receptor-positive breast cancer. Cancer Treatment Reviews. 67: 63-70. PMID 29763779 DOI: 10.1016/J.Ctrv.2018.04.015 |
0.508 |
|
| 2018 |
Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, ... ... Perou CM, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nature Medicine. PMID 29713086 DOI: 10.1038/S41591-018-0009-7 |
0.701 |
|
| 2018 |
Puvanesarajah S, Nyante SJ, Kuzmiak CM, Chen M, Tse CK, Sun X, Allott EH, Kirk EL, Carey LA, Perou CM, Olshan AF, Henderson LM, Troester MA. PAM50 and risk of recurrence scores for interval breast cancers. Cancer Prevention Research (Philadelphia, Pa.). PMID 29622545 DOI: 10.1158/1940-6207.Capr-17-0368 |
0.519 |
|
| 2018 |
Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, ... ... Perou CM, et al. Erratum: Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. 556: 135. PMID 29620732 DOI: 10.1038/nature26162 |
0.398 |
|
| 2018 |
Huo D, Perou CM, Olopade OI. Reported Biologic Differences in Breast Cancer by Race Due to Disparities in Screening-Reply. Jama Oncology. PMID 29543936 DOI: 10.1001/Jamaoncol.2017.5909 |
0.49 |
|
| 2018 |
Takaku M, Grimm SA, Roberts JD, Chrysovergis K, Bennett BD, Myers P, Perera L, Tucker CJ, Perou CM, Wade PA. GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nature Communications. 9: 1059. PMID 29535312 DOI: 10.1038/S41467-018-03478-4 |
0.504 |
|
| 2018 |
Sun W, Bunn P, Jin C, Little P, Zhabotynsky V, Perou CM, Hayes DN, Chen M, Lin DY. The association between copy number aberration, DNA methylation and gene expression in tumor samples. Nucleic Acids Research. PMID 29529299 DOI: 10.1093/Nar/Gky131 |
0.448 |
|
| 2018 |
Siegel MB, He X, Hoadley KA, Hoyle A, Pearce JB, Garrett AL, Kumar S, Moylan VJ, Brady CM, Van Swearingen AE, Marron D, Gupta GP, Thorne LB, Kieran N, Livasy C, ... ... Perou CM, et al. Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. The Journal of Clinical Investigation. PMID 29480819 DOI: 10.1172/Jci96153 |
0.762 |
|
| 2018 |
Knott SRV, Wagenblast E, Khan S, Kim SY, Soto M, Wagner M, Turgeon MO, Fish L, Erard N, Gable AL, Maceli AR, Dickopf S, Papachristou EK, D'Santos CS, Carey LA, ... ... Perou CM, et al. Asparagine bioavailability governs metastasis in a model of breast cancer. Nature. PMID 29414946 DOI: 10.1038/Nature25465 |
0.479 |
|
| 2018 |
Allott EH, Geradts J, Cohen SM, Khoury T, Zirpoli GR, Bshara W, Davis W, Omilian A, Nair P, Ondracek RP, Cheng TD, Miller CR, Hwang H, Thorne LB, O'Connor S, ... ... Perou CM, et al. Frequency of breast cancer subtypes among African American women in the AMBER consortium. Breast Cancer Research : Bcr. 20: 12. PMID 29409530 DOI: 10.1186/S13058-018-0939-5 |
0.53 |
|
| 2018 |
Echavarría I, López-Tarruella S, Picornell AC, Garcia-Saenz JA, Jerez-Gilarranz Y, Hoadley KA, Gomez H, Moreno F, Del Monte-Millán M, Marquez-Rodas I, Alvarez EL, Ramos-Medina R, Gayarre J, Massarrah T, Ocaña I, ... ... Perou CM, et al. Pathological response in a triple negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann's refined classification. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29378733 DOI: 10.1158/1078-0432.Ccr-17-1912 |
0.697 |
|
| 2018 |
Laurberg T, Tramm T, Nielsen T, Alsner J, Nord S, Myhre S, Sørlie T, Leung S, Fan C, Perou C, Gelmon K, Overgaard J, Voduc D, Prat A, Cheang MCU. Intrinsic subtypes and benefit from postmastectomy radiotherapy in node-positive premenopausal breast cancer patients who received adjuvant chemotherapy - results from two independent randomized trials. Acta Oncologica (Stockholm, Sweden). 57: 38-43. PMID 29172851 DOI: 10.1080/0284186X.2017.1401735 |
0.525 |
|
| 2018 |
Troester MA, Sun X, Allott EH, Geradts J, Cohen SM, Tse CK, Kirk EL, Thorne LB, Mathews M, Li Y, Hu Z, Robinson WR, Hoadley KA, Olopade OI, Reeder-Hayes KE, ... ... Perou CM, et al. Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study. Journal of the National Cancer Institute. 110. PMID 28859290 DOI: 10.1093/Jnci/Djx135 |
0.68 |
|
| 2018 |
Mayhew GM, Shibata Y, Sun J, Perou CM, Hayes DN, Lai-Goldman M, Faruki H. Bladder cancer gene expression subtypes (60 gene signature) to define prognosis, differential immune response, and biomarker associations. Journal of Clinical Oncology. 36: 4538-4538. DOI: 10.1200/Jco.2018.36.15_Suppl.4538 |
0.449 |
|
| 2018 |
Perou CM. Abstract IA12: Precision medicine for triple-negative breast cancer patients using a systems biology approach Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-Ia12 |
0.599 |
|
| 2018 |
Zurlo G, Simon J, Fan C, Robinson A, Martinez JR, Kriegsheim A, Locasale J, Perou C, Zhang Q. Abstract B18: ADSL controls pyrimidine metabolism and triple-negative breast tumorigenesis Molecular Cancer Research. 16. DOI: 10.1158/1557-3125.Advbc17-B18 |
0.544 |
|
| 2018 |
Takaku M, Grimm SA, Roberts JD, Chrysovergis K, Myers P, Perou CM, Wade PA. Abstract 5418: GATA3 zinc-finger mutation induces transcriptional reprogramming in breast cancer through gain and loss of function Cancer Research. 78: 5418-5418. DOI: 10.1158/1538-7445.Am2018-5418 |
0.569 |
|
| 2018 |
Vincent BG, Sambade M, Chai S, Siegel MB, Cuaboy L, Hoyle A, Parker J, Perou CM, Anders CK. Abstract 4055: Genomic and immune characterization of triple-negative breast cancer brain metastases Cancer Research. 78: 4055-4055. DOI: 10.1158/1538-7445.Am2018-4055 |
0.636 |
|
| 2018 |
Tanioka M, Parker JS, Henry LN, Tolaney S, Dang C, Krop IE, Harris L, Hillman D, Polley M, Berry DA, Winer EP, Carey LA, Perou CM. A prognostic model integrating clinical data and gene signatures in phase III neoadjuvant trial CALGB 40601 (Alliance) Annals of Oncology. 29: vii50. DOI: 10.1093/Annonc/Mdy373 |
0.488 |
|
| 2018 |
Faruki H, Mayhew G, Hayes D, Perou C, Lai-Goldman M. HNSCC Gene Expression Subtypes, Including a HPV Subtype, Demonstrate Differential Immune Cell and Biomarker Associations International Journal of Radiation Oncology*Biology*Physics. 100: 1366. DOI: 10.1016/J.Ijrobp.2017.12.152 |
0.31 |
|
| 2017 |
Witek MA, Aufforth RD, Wang H, Kamande JW, Jackson JM, Pullagurla SR, Hupert ML, Usary J, Wysham WZ, Hilliard D, Montgomery S, Bae-Jump V, Carey LA, Gehrig PA, Milowsky MI, ... Perou CM, et al. Discrete microfluidics for the isolation of circulating tumor cell subpopulations targeting fibroblast activation protein alpha and epithelial cell adhesion molecule. Npj Precision Oncology. 1. PMID 29657983 DOI: 10.1038/s41698-017-0028-8 |
0.324 |
|
| 2017 |
Parada H, Sun X, Fleming JM, Williams-DeVane CR, Kirk EL, Olsson LT, Perou CM, Olshan AF, Troester MA. Race-associated biological differences among luminal A and basal-like breast cancers in the Carolina Breast Cancer Study. Breast Cancer Research : Bcr. 19: 131. PMID 29228969 DOI: 10.1186/S13058-017-0914-6 |
0.541 |
|
| 2017 |
McRee AJ, Marcom PK, Moore DT, Zamboni WC, Kornblum ZA, Hu Z, Phipps R, Anders CK, Reeder-Hayes K, Carey LA, Weck KE, Perou CM, Dees EC. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer. Clinical Breast Cancer. PMID 29153866 DOI: 10.1016/J.Clbc.2017.10.014 |
0.462 |
|
| 2017 |
Williams LA, Nichols HB, Hoadley KA, Tse CK, Geradts J, Bell ME, Perou CM, Love MI, Olshan AF, Troester MA. Reproductive risk factor associations with lobular and ductal carcinoma in the Carolina Breast Cancer Study. Cancer Causes & Control : Ccc. PMID 29124544 DOI: 10.1007/S10552-017-0977-9 |
0.671 |
|
| 2017 |
Lundberg A, Lindström LS, Harrell JC, Falato C, Carlson JW, Wright PK, Foukakis T, Perou CM, Czene K, Bergh J, Tobin NP. Gene expression signatures and immunohistochemical subtypes add prognostic value to each other in breast cancer cohorts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28972043 DOI: 10.1158/1078-0432.Ccr-17-1535 |
0.551 |
|
| 2017 |
Tobin NP, Lundberg A, Lindström LS, Harrell JC, Foukakis T, Carlsson L, Einbeigi Z, Linderholm BK, Loman N, Malmberg M, Fernö M, Czene K, Perou CM, Bergh J, Hatschek T. PAM50 provides prognostic information when applied to the lymph node metastases of advanced breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28972041 DOI: 10.1158/1078-0432.Ccr-17-2301 |
0.554 |
|
| 2017 |
Taylor NA, Vick SC, Iglesia MD, Brickey WJ, Midkiff BR, McKinnon KP, Reisdorf S, Anders CK, Carey LA, Parker JS, Perou CM, Vincent BG, Serody JS. Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. The Journal of Clinical Investigation. PMID 28825599 DOI: 10.1172/Jci90499 |
0.652 |
|
| 2017 |
O'Flanagan CH, Rossi EL, McDonell SB, Chen X, Tsai YH, Parker JS, Usary J, Perou CM, Hursting SD. Metabolic reprogramming underlies metastatic potential in an obesity-responsive murine model of metastatic triple negative breast cancer. Npj Breast Cancer. 3: 26. PMID 28748213 DOI: 10.1038/s41523-017-0027-5 |
0.603 |
|
| 2017 |
Roarty K, Pfefferle AD, Creighton CJ, Perou CM, Rosen JM. Ror2-mediated alternative Wnt signaling regulates cell fate and adhesion during mammary tumor progression. Oncogene. 36: 5958-5968. PMID 28650466 DOI: 10.1038/Onc.2017.206 |
0.48 |
|
| 2017 |
Bower JJ, Vance LD, Psioda M, Smith-Roe SL, Simpson DA, Ibrahim JG, Hoadley KA, Perou CM, Kaufmann WK. Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells. Npj Breast Cancer. 3: 9. PMID 28649649 DOI: 10.1038/s41523-017-0009-7 |
0.703 |
|
| 2017 |
Nolan E, Savas P, Policheni AN, Darcy PK, Vaillant F, Mintoff CP, Dushyanthen S, Mansour M, Pang JB, Fox SB, Perou CM, Visvader JE, Gray DHD, Loi S, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Science Translational Medicine. 9. PMID 28592566 DOI: 10.1126/Scitranslmed.Aal4922 |
0.496 |
|
| 2017 |
Huo D, Hu H, Rhie SK, Gamazon ER, Cherniack AD, Liu J, Yoshimatsu TF, Pitt JJ, Hoadley KA, Troester M, Ru Y, Lichtenberg T, Sturtz LA, Shelley CS, Benz CC, ... ... Perou CM, et al. Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. Jama Oncology. PMID 28472234 DOI: 10.1001/Jamaoncol.2017.0595 |
0.695 |
|
| 2017 |
Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, ... ... Perou CM, et al. Corrigendum: Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nature Communications. 8: 15479. PMID 28440318 DOI: 10.1038/Ncomms15479 |
0.385 |
|
| 2017 |
Federico L, Chong Z, Zhang D, McGrail DJ, Zhao W, Jeong KJ, Vellano CP, Ju Z, Gagea M, Liu S, Mitra S, Dennison JB, Lorenzi PL, Cardnell R, Diao L, ... ... Perou CM, et al. A murine preclinical syngeneic transplantation model for breast cancer precision medicine. Science Advances. 3: e1600957. PMID 28439535 DOI: 10.1126/Sciadv.1600957 |
0.529 |
|
| 2017 |
Silva GO, Siegel MB, Mose LE, Parker JS, Sun W, Perou CM, Chen M. SynthEx: a synthetic-normal-based DNA sequencing tool for copy number alteration detection and tumor heterogeneity profiling. Genome Biology. 18: 66. PMID 28390427 DOI: 10.1186/S13059-017-1193-3 |
0.504 |
|
| 2017 |
Perez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. Journal of the National Cancer Institute. 109: 1-8. PMID 28376219 DOI: 10.1093/jnci/djw207 |
0.394 |
|
| 2017 |
Rojas PA, May M, Sequeira GR, Elia A, Alvarez M, Martínez P, Gonzalez P, Hewitt S, He X, Perou CM, Molinolo A, Gibbons L, Abba MC, Gass H, Lanari C. Progesterone Receptor Isoform Ratio: A Breast Cancer Prognostic and Predictive Factor for Antiprogestin Responsiveness. Journal of the National Cancer Institute. 109. PMID 28376177 DOI: 10.1093/Jnci/Djw317 |
0.513 |
|
| 2017 |
Huang KL, Li S, Mertins P, Cao S, Gunawardena HP, Ruggles KV, Mani DR, Clauser KR, Tanioka M, Usary J, Kavuri SM, Xie L, Yoon C, Qiao JW, Wrobel J, ... ... Perou CM, et al. Proteogenomic integration reveals therapeutic targets in breast cancer xenografts. Nature Communications. 8: 14864. PMID 28348404 DOI: 10.1038/Ncomms14864 |
0.447 |
|
| 2017 |
Faruki H, Mayhew GM, Serody JS, Hayes DN, Perou CM, Lai-Goldman M. Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28341226 DOI: 10.1016/J.Jtho.2017.03.010 |
0.338 |
|
| 2017 |
Cejalvo JM, Martínez de Dueñas E, Galvan P, García-Recio S, Burgués Gasión O, Paré L, Antolin S, Martinello R, Blancas I, Adamo B, Guerrero-Zotano A, Muñoz M, Nuciforo P, Vidal M, Pérez RM, ... ... Perou CM, et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Research. PMID 28249905 DOI: 10.1158/0008-5472.Can-16-2717 |
0.552 |
|
| 2017 |
Thomas C, Henry W, Cuiffo BG, Collmann AY, Marangoni E, Benhamo V, Bhasin MK, Fan C, Fuhrmann L, Baldwin AS, Perou C, Vincent-Salomon A, Toker A, Karnoub AE. Pentraxin-3 is a PI3K signaling target that promotes stem cell-like traits in basal-like breast cancers. Science Signaling. 10. PMID 28223411 DOI: 10.1126/Scisignal.Aah4674 |
0.469 |
|
| 2017 |
Mehta GA, Parker JS, Silva GO, Hoadley KA, Perou CM, Gatza ML. Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer. Breast Cancer Research and Treatment. PMID 28176176 DOI: 10.1007/S10549-017-4139-2 |
0.776 |
|
| 2017 |
Zawistowski JS, Bevill SM, Goulet DR, Stuhlmiller TJ, Beltran AS, Olivares-Quintero JF, Singh D, Sciaky N, Parker JS, Rashid NU, Chen X, Duncan JS, Whittle MC, Angus SP, Velarde SH, ... ... Perou CM, et al. Enhancer Remodeling During Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacological Targeting of the P-TEFb Complex. Cancer Discovery. PMID 28108460 DOI: 10.1158/2159-8290.Cd-16-0653 |
0.569 |
|
| 2017 |
Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER. Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Plos Medicine. 14: e1002222. PMID 28068332 DOI: 10.1371/journal.pmed.1002222 |
0.731 |
|
| 2017 |
Perez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, Necela BM, Carr JM, Ferree S, Perou CM, Baehner F, Cheang MC, Thompson EA. Intrinsic Subtype and Therapeutic Response Among HER2-Positive Breaty st Tumors from the NCCTG (Alliance) N9831 Trial. Journal of the National Cancer Institute. 109. PMID 27794124 DOI: 10.1093/Jnci/Djw207 |
0.419 |
|
| 2017 |
Sledge GW, Chagpar A, Perou C. Collective Wisdom: Lobular Carcinoma of the Breast. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 35: 18-21. PMID 27249682 DOI: 10.14694/EDBK_100002 |
0.336 |
|
| 2017 |
Tanioka M, Garay J, Fan C, Carey LA, Perou CM. Genetic causes of resistance to entinostat in luminal breast cancer model systems. Journal of Clinical Oncology. 35: 1065-1065. DOI: 10.1200/Jco.2017.35.15_Suppl.1065 |
0.524 |
|
| 2017 |
Angus SP, Stuhlmiller T, Sciaky N, Chen X, Naim R, Tanioka M, Gallagher KK, Forero A, Krop IE, Thompson AM, Murthy RK, He X, Perou CM, Earp S, Carey LA, et al. TBCRC 036: Window of opportunity clinical trial reveals adaptive kinome reprogramming in single and combination HER2-targeting in breast cancer (BrCa). Journal of Clinical Oncology. 35: 1027-1027. DOI: 10.1200/Jco.2017.35.15_Suppl.1027 |
0.348 |
|
| 2017 |
Tobin N, Lundberg A, Lindström L, Harrell J, Brage SE, Stolt MF, Einbeigi Z, Loman N, Malmberg M, Perou C, Bergh J, Hatschek T. Abstract P1-07-16: Multi-level gene expression signatures provide significant prognostic information in metastatic breast cancer patients Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P1-07-16 |
0.529 |
|
| 2017 |
Vick SC, Taylor NA, Iglesia MD, Brickey WJ, Carey LA, Midkiff BR, McKinnon KP, Reisdorf S, Parker JS, Perou CM, Vincent BG, Serody JS. Abstract 568: Regulatory T cell recruitment limits the effectiveness of checkpoint inhibition for claudin-low breast cancer Immunology. 77: 568-568. DOI: 10.1158/1538-7445.Am2017-568 |
0.633 |
|
| 2017 |
Meric-Bernstam F, Evans K, Zheng X, Su X, Yuca E, Scott S, Akcakanat A, Ueno N, Lim B, Litton J, Valero V, Symmans F, Hortobagyi G, Perou C, Tripathy D, et al. Abstract 4970: Oxidative phosphorylation as a target in triple negative breast cancer therapy Cancer Research. 77: 4970-4970. DOI: 10.1158/1538-7445.Am2017-4970 |
0.503 |
|
| 2017 |
Hollern DP, Hoadley K, Vincent B, Perou CM. Abstract 3703: A genomic characterization of testicular germ cell tumor immune microenvironment Cancer Research. 77: 3703-3703. DOI: 10.1158/1538-7445.Am2017-3703 |
0.417 |
|
| 2017 |
Mose LE, Hayes DN, Perou CM, Parker JS. Abstract 3592: Improved indel detection in RNA-seq data via assembly based re-alignment reveals expressed Epidermal Growth Factor Receptor indels in Lung Adenocarcinoma Cancer Research. 77: 3592-3592. DOI: 10.1158/1538-7445.Am2017-3592 |
0.475 |
|
| 2017 |
Recio SG, Fan C, Siegel M, Parker JS, Duronio GN, Prat A, Perou CM. Abstract 3119: Identification of genetic drivers in HER2enriched/HER2negative breast cancer Cancer Research. 77: 3119-3119. DOI: 10.1158/1538-7445.Am2017-3119 |
0.725 |
|
| 2017 |
Silva-Fisher JM, Eteleeb AM, Nielsen T, Perou CM, Reis-Filho JS, Ellis MJ, Mardis ER, Maher CA. Abstract 2547: Discovery and characterization of late-stage breast cancer estrogen receptor alpha 1 bound long non-coding RNAs Cancer Research. 77: 2547-2547. DOI: 10.1158/1538-7445.Am2017-2547 |
0.523 |
|
| 2017 |
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Matsunuma R, He X, Singh P, Kosaka Y, Crowder R, Haricharan S, Kavuri S, Hoog J, Phommaly C, Goncalves R, ... ... Perou C, et al. Abstract 1033: Estrogen receptor gene fusions drive endocrine therapy resistance in estrogen receptor positive breast cancer Cancer Research. 77: 1033-1033. DOI: 10.1158/1538-7445.Am2017-1033 |
0.686 |
|
| 2017 |
Picornell A, Echavarria Diaz-Guardamino I, Alvarez Castillo E, Lopez-Tarruella Cobo S, Jerez Y, Hoadley K, Parker J, del Monte-Millán M, Ramos Medina R, Gayarre J, Ocaña I, Cebollero M, Massarrah T, Moreno Antón F, García-Saenz J, ... ... Perou C, et al. Breast cancer PAM50 subtypes: Correlation between RNA-Seq and multiplexed gene expression platforms Annals of Oncology. 28: v56-v57. DOI: 10.1093/Annonc/Mdx362.036 |
0.751 |
|
| 2017 |
Echavarria Diaz-Guardamino I, Picornell A, López-Tarruella S, Jerez Y, Hoadley K, Alvarez E, del Monte-Millán M, Gayarre J, Ramos-Medina R, Massarrah T, Ocaña I, Cebollero M, Moreno Antón F, García-Saenz J, Gomez Moreno H, ... ... Perou C, et al. Pathological response in a triple-negative breast cancer cohort treated with neoadjuvant carboplatin and docetaxel according to Lehmann’s refined classification (TNBCtype-4) Annals of Oncology. 28: v48. DOI: 10.1093/Annonc/Mdx362.013 |
0.704 |
|
| 2016 |
Troester MA, Hoadley KA, D'Arcy M, Cherniack AD, Stewart C, Koboldt DC, Robertson AG, Mahurkar S, Shen H, Wilkerson MD, Sandhu R, Johnson NB, Allison KH, Beck AH, Yau C, ... ... Perou CM, et al. DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. Npj Breast Cancer. 2: 16007. PMID 28721375 DOI: 10.1038/npjbcancer.2016.7 |
0.664 |
|
| 2016 |
Liu MC, Pitcher BN, Mardis ER, Davies SR, Friedman PN, Snider JE, Vickery TL, Reed JP, DeSchryver K, Singh B, Gradishar WJ, Perez EA, Martino S, Citron ML, Norton L, ... ... Perou CM, et al. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). Npj Breast Cancer. 2. PMID 28691057 DOI: 10.1038/npjbcancer.2015.23 |
0.369 |
|
| 2016 |
Bowerman CJ, Byrne JD, Chu KS, Schorzman AN, Keeler AW, Sherwood CA, Perry JL, Luft JC, Darr DB, Deal AM, Napier ME, Zamboni WC, Sharpless NE, Perou C, DeSimone JM. Docetaxel-loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. Nano Letters. PMID 27966988 DOI: 10.1021/Acs.Nanolett.6B03971 |
0.533 |
|
| 2016 |
Hoadley KA, Siegel MB, Kanchi KL, Miller CA, Ding L, Zhao W, He X, Parker JS, Wendl MC, Fulton RS, Demeter RT, Wilson RK, Carey LA, Perou CM, Mardis ER. Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. Plos Medicine. 13: e1002174. PMID 27923045 DOI: 10.1371/Journal.Pmed.1002174 |
0.736 |
|
| 2016 |
Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, de la Haba-Rodríguez J, Arcusa A, Chacón I, Sánchez-Rovira P, Plazaola A, Muñoz M, Paré L, Parker JS, Ribelles N, ... ... Perou CM, et al. A PAM50-based Chemo-Endocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27903675 DOI: 10.1158/1078-0432.Ccr-16-2092 |
0.657 |
|
| 2016 |
Heng YJ, Lester SC, Tse GM, Factor RE, Allison KH, Collins LC, Chen YY, Jensen KC, Johnson NB, Jeong JC, Punjabi R, Shin SJ, Singh K, Krings G, Eberhard DA, ... ... Perou CM, et al. The molecular basis of breast cancer pathological phenotypes. The Journal of Pathology. PMID 27861902 DOI: 10.1002/Path.4847 |
0.73 |
|
| 2016 |
Reaves DK, Hoadley KA, Fagan-Solis K, Jima DD, Bereman M, Thorpe L, Hicks J, McDonald D, Troester MA, Perou CM, Fleming JM. Nuclear localized LSR, a novel regulator of breast cancer behavior and tumorigenesis. Molecular Cancer Research : McR. PMID 27856957 DOI: 10.1158/1541-7786.Mcr-16-0085-T |
0.696 |
|
| 2016 |
Li H, Zhu Y, Burnside ES, Huang E, Drukker K, Hoadley KA, Fan C, Conzen SD, Zuley M, Net JM, Sutton E, Whitman GJ, Morris E, Perou CM, Ji Y, et al. Quantitative MRI radiomics in the prediction of molecular classifications of breast cancer subtypes in the TCGA/TCIA data set. Npj Breast Cancer. 2. PMID 27853751 DOI: 10.1038/npjbcancer.2016.12 |
0.664 |
|
| 2016 |
Gupta GP, Ho AY, Feng W, Fan C, Akram M, Brogi E, Powell SN, Perou CM, Wen YH, Petrini JH. Mre11 Dysfunction Is Associated With Triple-Negative Breast Cancer and Confers Sensitivity to DNA Damaging Therapy. International Journal of Radiation Oncology, Biology, Physics. 96: S43. PMID 27675928 DOI: 10.1016/J.Ijrobp.2016.06.115 |
0.477 |
|
| 2016 |
Mose LE, Selitsky SR, Bixby LM, Marron DL, Iglesia MD, Serody JS, Perou CM, Vincent BG, Parker JS. Assembly-based inference of B-cell receptor repertoires from short read RNA sequencing data with V'DJer. Bioinformatics (Oxford, England). PMID 27559159 DOI: 10.1093/Bioinformatics/Btw526 |
0.486 |
|
| 2016 |
Iglesia MD, Parker JS, Hoadley KA, Serody JS, Perou CM, Vincent BG. Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. Journal of the National Cancer Institute. 108. PMID 27335052 DOI: 10.1093/Jnci/Djw144 |
0.674 |
|
| 2016 |
He Z, Wan X, Schulz A, Bludau H, Dobrovolskaia MA, Stern ST, Montgomery SA, Yuan H, Li Z, Alakhova D, Sokolsky M, Darr DB, Perou CM, Jordan R, Luxenhofer R, et al. A high capacity polymeric micelle of paclitaxel: Implication of high dose drug therapy to safety and in vivo anti-cancer activity. Biomaterials. 101: 296-309. PMID 27315213 DOI: 10.1016/J.Biomaterials.2016.06.002 |
0.393 |
|
| 2016 |
Zhang H, Qi J, Reyes JM, Li L, Rao PK, Li F, Lin CY, Perry JA, Lawlor MA, Federation A, De Raedt T, Li YY, Liu Y, Duarte MA, Zhang Y, ... ... Perou CM, et al. Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discovery. PMID 27312177 DOI: 10.1158/2159-8290.Cd-16-0164 |
0.395 |
|
| 2016 |
Sharma P, López-Tarruella S, García-Saenz JA, Ward C, Connor C, Gómez HL, Prat A, Moreno F, Jerez-Gilarranz Y, Barnadas A, Picornell A, Del Monte-Millán M, Gonzalez-Rivera M, Massarrah T, Pelaez-Lorenzo B, ... ... Perou CM, et al. Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: Combined analysis of two cohorts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27301700 DOI: 10.1158/1078-0432.Ccr-16-0162 |
0.522 |
|
| 2016 |
Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, Kawaler E, Mundt F, Krug K, Tu Z, Lei JT, ... ... Perou CM, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 534: 55-62. PMID 27251275 DOI: 10.1038/Nature18003 |
0.538 |
|
| 2016 |
Lawson CD, Fan C, Mitin N, Baker NM, George SD, Graham DM, Perou CM, Burridge K, Der CJ, Rossman KL. Rho GTPase Transcriptome Analysis Reveals Oncogenic Roles for Rho GTPase-activating Proteins in Basal-like Breast Cancers. Cancer Research. PMID 27216196 DOI: 10.1158/0008-5472.Can-15-2923 |
0.555 |
|
| 2016 |
Dennison JB, Shahmoradgoli M, Liu W, Ju Z, Meric-Bernstam F, Perou CM, Sahin A, Welm AL, Oesterreich S, Sikora MJ, Brown RE, Mills GB. High intra-tumoral stromal content defines Reactive breast cancer as a low-risk breast cancer subtype. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27172895 DOI: 10.1158/1078-0432.Ccr-16-0171 |
0.586 |
|
| 2016 |
Pfefferle AD, Agrawal YN, Koboldt DC, Kanchi KL, Herschkowitz JI, Mardis ER, Rosen JM, Perou CM. Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53 deficient mammary cancers. Disease Models & Mechanisms. PMID 27149990 DOI: 10.1242/Dmm.025239 |
0.785 |
|
| 2016 |
Li H, Zhu Y, Burnside ES, Drukker K, Hoadley KA, Fan C, Conzen SD, Whitman GJ, Sutton EJ, Net JM, Ganott M, Huang E, Morris EA, Perou CM, Ji Y, et al. MR Imaging Radiomics Signatures for Predicting the Risk of Breast Cancer Recurrence as Given by Research Versions of MammaPrint, Oncotype DX, and PAM50 Gene Assays. Radiology. 152110. PMID 27144536 DOI: 10.1148/Radiol.2016152110 |
0.698 |
|
| 2016 |
Usary J, Darr DB, Pfefferle AD, Perou CM. Overview of Genetically Engineered Mouse Models of Distinct Breast Cancer Subtypes. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. 72: 14.38.1-14.38.11. PMID 26995547 DOI: 10.1002/0471141755.Ph1438S72 |
0.571 |
|
| 2016 |
Becker MA, Ibrahim YH, Oh AS, Fagan DH, Byron SA, Sarver AL, Lee AV, Shaw LM, Fan C, Perou CM, Yee D. Insulin Receptor Substrate Adaptor Proteins Mediate Prognostic Gene Expression Profiles in Breast Cancer. Plos One. 11: e0150564. PMID 26991655 DOI: 10.1371/Journal.Pone.0150564 |
0.532 |
|
| 2016 |
Zhao W, Hoadley KA, Parker JS, Perou CM. Identification of mRNA isoform switching in breast cancer. Bmc Genomics. 17: 181. PMID 26939613 DOI: 10.1186/S12864-016-2521-9 |
0.756 |
|
| 2016 |
Martin M, Brase JC, Ruiz A, Prat A, Kronenwett R, Calvo L, Petry C, Bernard PS, Ruiz-Borrego M, Weber KE, Rodriguez CA, Alvarez IM, Segui MA, Perou CM, Casas M, et al. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study. Breast Cancer Research and Treatment. PMID 26909792 DOI: 10.1007/S10549-016-3725-Z |
0.438 |
|
| 2016 |
Faruki H, Mayhew G, Hayes DN, Serody JS, Perou CM, Lai-Goldman M. Immune cell activation among lung adenocarcinoma and squamous cell carcinoma intrinsic subtypes and CD274 (PD-L1) expression. Journal of Clinical Oncology. 34: 3077-3077. DOI: 10.1200/Jco.2016.34.15_Suppl.3077 |
0.301 |
|
| 2016 |
Mertins P, Mani, Ruggles K, Gillette M, Clauser K, Wang P, Wang X, Qiao J, Cao S, Petralia F, Mundt F, Tu Z, Lei J, Gatza M, Wilkerson M, ... Perou C, et al. Abstract IA29: Proteogenomic and phosphoproteomic analysis of breast cancer Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Advbc15-Ia29 |
0.578 |
|
| 2016 |
Tanioka M, Usary J, Darr D, Harrell C, Perou C. Abstract P5-03-05: Genomic analysis and efficacy of entinostat in basal-like and HER2-overexpressing models Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P5-03-05 |
0.312 |
|
| 2016 |
Zheng Z, Bu W, Tian L, Fan C, Gao X, Zhang X, Yu C, Wang H, Liao Y, Li Y, Lewis M, Edwards D, Zwaka T, Hilsenbeck S, Medina D, ... Perou C, et al. Abstract P2-06-11: Wild type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL8 secretion via JAK2 activation Cancer Research. 75: 2139-2139. DOI: 10.1158/1538-7445.Sabcs15-P2-06-11 |
0.466 |
|
| 2016 |
Dance-Barnes ST, Evans E, Steward S, He X, Usary J, Perou C. Abstract A24: Characterization of a novel p53; BRCA1-deficient claudin-low mammary tumor cell line Cancer Research. 76. DOI: 10.1158/1538-7445.Fbcr15-A24 |
0.468 |
|
| 2016 |
Han YJ, Zhang J, Mason JM, Prat A, Yoshimatsu T, Perou CM, Kwon J, Kannanganattu P, Olopade OI. Abstract 994: Long noncoding RNAs generated from the BRCA1 pseudogene regulate genomic instability and homologous recombination repair Cancer Research. 76: 994-994. DOI: 10.1158/1538-7445.Am2016-994 |
0.476 |
|
| 2016 |
Silva-Fisher JM, Eteleeb AM, Nielsen TO, Perou CM, Reis-Filho JS, Ellis MJ, Mardis ER, Maher CA. Abstract 993: Identification of estrogen receptor alpha 1 bound lncRNAs in aggressive breast cancer Cancer Research. 76: 993-993. DOI: 10.1158/1538-7445.Am2016-993 |
0.547 |
|
| 2016 |
Roarty K, Pfefferle AD, Creighton CJ, Perou CM, Rosen JM. Abstract 3306: Wnt pathway dynamics in breast cancer progression Cancer Research. 76: 3306-3306. DOI: 10.1158/1538-7445.Am2016-3306 |
0.498 |
|
| 2016 |
Heng YJJ, Jeong JC, Gendoo DMA, Haibe-Kains B, Ciriello G, Hoadley KA, Perou CM, Beck AH. Abstract 2627: Molecular analyses of histopathologic morphologic features in breast cancer Cancer Research. 76: 2627-2627. DOI: 10.1158/1538-7445.Am2016-2627 |
0.721 |
|
| 2016 |
Kumar M, DeVaux RS, Shen JJ, Davis SP, Dinger ME, Mattick JS, Perou CM, Rosen JM, Mani SA, Herschkowitz JI. Abstract 1598: LncRNA AK001796 as a therapeutic target in aggressive breast cancers Cancer Research. 76: 1598-1598. DOI: 10.1158/1538-7445.Am2016-1598 |
0.567 |
|
| 2016 |
Diaz-Guardamino IE, Lopez-Tarruella S, García-Sáenz J, Moreno HG, Moreno F, Jerez Y, Fuentes H, Marquez-Rodas I, Cebollero M, Del Monte-Millan M, Picornell A, Massarrah T, Barnadas A, Prat A, García AB, ... ... Perou C, et al. Intrinsic subtype and response to neoadjuvant chemotherapy with carboplatin and docetaxel (TCb) in triple-negative breast cancer (TNBC) Annals of Oncology. 27: vi56. DOI: 10.1093/Annonc/Mdw364.44 |
0.538 |
|
| 2015 |
Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, Minn AJ, Cryns VL, Cheang MC. αB-crystallin Expression in Breast Cancer is Associated with Brain Metastasis. Npj Breast Cancer. 1. PMID 27656679 DOI: 10.1038/npjbcancer.2015.14 |
0.389 |
|
| 2015 |
Allott EH, Cohen SM, Geradts J, Sun X, Khoury T, Bshara W, Zirpoli GR, Miller CR, Hwang H, Thorne LB, O'Connor S, Tse CK, Bell MB, Hu Z, Li Y, ... ... Perou CM, et al. Performance of three biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER consortium. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 26711328 DOI: 10.1158/1055-9965.Epi-15-0874 |
0.528 |
|
| 2015 |
Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, et al. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nature Communications. 6: 10077. PMID 26687066 DOI: 10.1038/Ncomms10077 |
0.308 |
|
| 2015 |
Wang P, Wu J, Ma S, Zhang L, Yao J, Hoadley KA, Wilkerson MD, Perou CM, Guan KL, Ye D, Xiong Y. Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents. Cell Reports. PMID 26686626 DOI: 10.1016/J.Celrep.2015.11.029 |
0.539 |
|
| 2015 |
Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, Viladot M, Pineda E, Arance A, Muñoz M, Paré L, Cheang MC, Adamo B, Perou CM. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. Bmc Medicine. 13: 303. PMID 26684470 DOI: 10.1186/S12916-015-0540-Z |
0.684 |
|
| 2015 |
Ruggles KV, Tang Z, Wang X, Grover H, Askenazi M, Teubl J, Cao S, McLellan MD, Clauser KR, Tabb DL, Mertins P, Slebos R, Erdmann-Gilmore P, Li S, Gunawardena HP, ... ... Perou CM, et al. An analysis of the sensitivity of proteogenomic mapping of somatic mutations and novel splicing events in cancer. Molecular & Cellular Proteomics : McP. PMID 26631509 DOI: 10.1074/Mcp.M115.056226 |
0.61 |
|
| 2015 |
Hu YJ, Sun W, Tzeng JY, Perou CM. Proper Use of Allele-Specific Expression Improves Statistical Power for cis-eQTL Mapping with RNA-Seq Data. Journal of the American Statistical Association. 110: 962-974. PMID 26568645 DOI: 10.1080/01621459.2015.1038449 |
0.368 |
|
| 2015 |
Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, ... ... Perou CM, et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. The New England Journal of Medicine. PMID 26536169 DOI: 10.1056/Nejmoa1505917 |
0.634 |
|
| 2015 |
Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, Ollila DW, Krop IE, Henry NL, Weckstein DJ, Anders CK, Singh B, Hoadley KA, Iglesia M, Cheang MC, ... Perou CM, et al. Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26527775 DOI: 10.1200/Jco.2015.62.1268 |
0.593 |
|
| 2015 |
Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, Bowlby R, Shen H, Hayat S, Fieldhouse R, Lester SC, ... ... Perou CM, et al. Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 163: 506-19. PMID 26451490 DOI: 10.1016/J.Cell.2015.09.033 |
0.721 |
|
| 2015 |
Faruki H, Mayhew GM, Fan C, Wilkerson MD, Parker S, Kam-Morgan L, Eisenberg M, Horten B, Hayes DN, Perou CM, Lai-Goldman M. Validation of the Lung Subtyping Panel in Multiple Fresh-Frozen and Formalin-Fixed, Paraffin-Embedded Lung Tumor Gene Expression Data Sets. Archives of Pathology & Laboratory Medicine. PMID 26430809 DOI: 10.5858/Arpa.2015-0113-Oa |
0.4 |
|
| 2015 |
Dravis C, Spike BT, Harrell JC, Johns C, Trejo CL, Southard-Smith EM, Perou CM, Wahl GM. Sox10 Regulates Stem/Progenitor and Mesenchymal Cell States in Mammary Epithelial Cells. Cell Reports. 12: 2035-48. PMID 26365194 DOI: 10.1016/J.Celrep.2015.08.040 |
0.377 |
|
| 2015 |
Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S, Liu S, Leung S, Geiss G, Snider J, Vickery T, Davies SR, Mardis ER, Gnant M, Sestak I, ... ... Perou CM, et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. Bmc Medical Genomics. 8: 54. PMID 26297356 DOI: 10.1186/S12920-015-0129-6 |
0.666 |
|
| 2015 |
Parker JS, Perou CM. Tumor Heterogeneity: Focus on the Leaves, the Trees, or the Forest? Cancer Cell. 28: 149-50. PMID 26267531 DOI: 10.1016/J.Ccell.2015.07.011 |
0.6 |
|
| 2015 |
Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, ... ... Perou CM, et al. Corrigendum: Progesterone receptor modulates ERα action in breast cancer. Nature. 526: 144. PMID 26245370 DOI: 10.1038/Nature14959 |
0.454 |
|
| 2015 |
Carey LA, Perou CM. Palbociclib--Taking Breast-Cancer Cells Out of Gear. The New England Journal of Medicine. 373: 273-4. PMID 26176385 DOI: 10.1056/Nejme1506680 |
0.481 |
|
| 2015 |
Zheng ZY, Tian L, Bu W, Fan C, Gao X, Wang H, Liao YH, Li Y, Lewis MT, Edwards D, Zwaka TP, Hilsenbeck SG, Medina D, Perou CM, Creighton CJ, et al. Wild-Type N-Ras, Overexpressed in Basal-like Breast Cancer, Promotes Tumor Formation by Inducing IL-8 Secretion via JAK2 Activation. Cell Reports. PMID 26166574 DOI: 10.1016/J.Celrep.2015.06.044 |
0.411 |
|
| 2015 |
Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AA, Serandour AA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, ... ... Perou CM, et al. Progesterone receptor modulates ERα action in breast cancer. Nature. 523: 313-7. PMID 26153859 DOI: 10.1038/Nature14583 |
0.555 |
|
| 2015 |
Ligibel JA, Cirrincione CT, Liu M, Citron M, Ingle JN, Gradishar W, Martino S, Sikov W, Michaelson R, Mardis E, Perou CM, Ellis M, Winer E, Hudis CA, Berry D, et al. Body Mass Index, PAM50 Subtype, and Outcomes in Node-Positive Breast Cancer: CALGB 9741 (Alliance). Journal of the National Cancer Institute. 107. PMID 26113580 DOI: 10.1093/Jnci/Djv179 |
0.481 |
|
| 2015 |
Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, Moulder SL, Marcom PK, Ma J, Rosen JM, Perou CM. Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer. Breast Cancer Research and Treatment. PMID 26109346 DOI: 10.1007/S10549-015-3476-2 |
0.704 |
|
| 2015 |
D'Arcy M, Fleming J, Robinson WR, Kirk EL, Perou CM, Troester MA. Race-associated biological differences among Luminal A breast tumors. Breast Cancer Research and Treatment. PMID 26109344 DOI: 10.1007/S10549-015-3474-4 |
0.563 |
|
| 2015 |
Black JL, Harrell JC, Leisner TM, Fellmeth MJ, George SD, Reinhold D, Baker NM, Jones CD, Der CJ, Perou CM, Parise LV. CIB1 depletion impairs cell survival and tumor growth in triple-negative breast cancer. Breast Cancer Research and Treatment. PMID 26105795 DOI: 10.1007/S10549-015-3458-4 |
0.549 |
|
| 2015 |
Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, ... ... Perou CM, et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. The New England Journal of Medicine. 372: 2481-98. PMID 26061751 DOI: 10.1056/Nejmoa1402121 |
0.625 |
|
| 2015 |
Cantrell MA, Ebelt ND, Pfefferle AD, Perou CM, Van Den Berg CL. c-Jun N-terminal kinase 2 prevents luminal cell commitment in normal mammary glands and tumors by inhibiting p53/Notch1 and breast cancer gene 1 expression. Oncotarget. 6: 11863-81. PMID 25970777 DOI: 10.18632/Oncotarget.3787 |
0.565 |
|
| 2015 |
Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, ... ... Perou CM, et al. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Molecular & Cellular Proteomics : McP. 14: 1959-76. PMID 25953087 DOI: 10.1074/Mcp.M115.049783 |
0.435 |
|
| 2015 |
Schott AF, Perou CM, Hayes DF. Genome Medicine in Cancer: What's in a Name? Cancer Research. 75: 1930-5. PMID 25920349 DOI: 10.1158/0008-5472.Can-15-0174 |
0.347 |
|
| 2015 |
Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, ... ... Perou CM, et al. Defining breast cancer intrinsic subtypes by quantitative receptor expression. The Oncologist. 20: 474-82. PMID 25908555 DOI: 10.1634/Theoncologist.2014-0372 |
0.668 |
|
| 2015 |
Nielsen TO, Perou CM. CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 1779-81. PMID 25878358 DOI: 10.1158/1078-0432.Ccr-14-2552 |
0.485 |
|
| 2015 |
Wagenblast E, Soto M, Gutiérrez-Ángel S, Hartl CA, Gable AL, Maceli AR, Erard N, Williams AM, Kim SY, Dickopf S, Harrell JC, Smith AD, Perou CM, Wilkinson JE, Hannon GJ, et al. A model of breast cancer heterogeneity reveals vascular mimicry as a driver of metastasis. Nature. 520: 358-62. PMID 25855289 DOI: 10.1038/Nature14403 |
0.502 |
|
| 2015 |
Welch JD, Baran-Gale J, Perou CM, Sethupathy P, Prins JF. Pseudogenes transcribed in breast invasive carcinoma show subtype-specific expression and ceRNA potential. Bmc Genomics. 16: 113. PMID 25765044 DOI: 10.1186/S12864-015-1227-8 |
0.527 |
|
| 2015 |
Knezevic J, Pfefferle AD, Petrovic I, Greene SB, Perou CM, Rosen JM. Expression of miR-200c in claudin-low breast cancer alters stem cell functionality, enhances chemosensitivity and reduces metastatic potential. Oncogene. PMID 25746005 DOI: 10.1038/Onc.2015.48 |
0.438 |
|
| 2015 |
Zhang M, Tsimelzon A, Chang CH, Fan C, Wolff A, Perou CM, Hilsenbeck SG, Rosen JM. Intratumoral heterogeneity in a Trp53-null mouse model of human breast cancer. Cancer Discovery. 5: 520-33. PMID 25735774 DOI: 10.1158/2159-8290.Cd-14-1101 |
0.522 |
|
| 2015 |
He Z, Schulz A, Wan X, Seitz J, Bludau H, Alakhova DY, Darr DB, Perou CM, Jordan R, Ojima I, Kabanov AV, Luxenhofer R. Poly(2-oxazoline) based micelles with high capacity for 3rd generation taxoids: preparation, in vitro and in vivo evaluation. Journal of Controlled Release : Official Journal of the Controlled Release Society. 208: 67-75. PMID 25725361 DOI: 10.1016/J.Jconrel.2015.02.024 |
0.302 |
|
| 2015 |
Pfefferle AD, Spike BT, Wahl GM, Perou CM. Luminal progenitor and fetal mammary stem cell expression features predict breast tumor response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 149: 425-37. PMID 25575446 DOI: 10.1007/S10549-014-3262-6 |
0.585 |
|
| 2015 |
Goetz MP, Sun JX, Suman VJ, Silva GO, Perou CM, Nakamura Y, Cox NJ, Stephens PJ, Miller VA, Ross JS, Chen D, Safgren SL, Kuffel MJ, Ames MM, Kalari KR, et al. Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies. Journal of the National Cancer Institute. 107. PMID 25490892 DOI: 10.1093/Jnci/Dju401 |
0.463 |
|
| 2015 |
Tobin NP, Harrell JC, Lövrot J, Egyhazi Brage S, Frostvik Stolt M, Carlsson L, Einbeigi Z, Linderholm B, Loman N, Malmberg M, Walz T, Fernö M, Perou CM, Bergh J, Hatschek T, et al. Molecular subtype and tumor characteristics of breast cancer metastases as assessed by gene expression significantly influence patient post-relapse survival. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 81-8. PMID 25361981 DOI: 10.1093/Annonc/Mdu498 |
0.595 |
|
| 2015 |
Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 13-21. PMID 25092775 DOI: 10.1200/Jco.2014.57.0572 |
0.472 |
|
| 2015 |
May M, Rojas P, Sequeira G, Elia A, Martinez Vazquez P, Gonzalez P, Abba MC, Molinolo A, Hewitt SM, Perou CM, Gass H, Lanari C. Progesterone receptor isoform ratio to define the molecular signature of luminal breast cancers and their antiprogestin responsiveness. Journal of Clinical Oncology. 33: 11016-11016. DOI: 10.1200/Jco.2015.33.15_Suppl.11016 |
0.48 |
|
| 2015 |
Sikov WM, Barry WT, Hoadley KA, Pitcher BN, Singh B, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Berry DA, Hahn OM, Carey LA, Perou CM, et al. Abstract S4-05: Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC) after neoadjuvant chemotherapy (NACT) +/- carboplatin (Cb) or bevacizumab (Bev): CALGB 40603/150709 (Allianc Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S4-05 |
0.703 |
|
| 2015 |
Hoadley KA, Barry WT, Pitcher BN, Parker JS, Wilkerson MD, Irvin W, Henry NL, Tolaney SM, Dang C, Krop IE, Berry DA, Mardis ER, Perou CM, Winer EP, Hudis CA, et al. Abstract S3-06: Mutational analysis of CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel (T) and trastuzumab (H) with or without lapatinib (L) for HER2-positive breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S3-06 |
0.745 |
|
| 2015 |
Ciriello G, Gatza ML, Hoadley KA, Zhang H, Rhie SK, Bowlby R, Wilkerson MD, Kandoth C, McLellan M, Cherniack A, Laird PW, Sander C, King TA, Perou CM. Abstract S2-04: Comprehensive molecular characterization of invasive lobular breast tumors Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S2-04 |
0.73 |
|
| 2015 |
Dixon JM, Turnbull AK, Fan C, Parker JS, He X, Arthur L, Martinez-Perez C, Renshaw L, Perou C. Abstract S1-05: In-depth genomic analysis of ER+ breast cancers during development of endocrine resistance Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-S1-05 |
0.668 |
|
| 2015 |
Shao J, Zhang J, Crowder RJ, Goncalves R, Phommaly C, Awg B, Perou CM, Maher CA, Thompson EA, Ellis MJ. Abstract PD6-4: ESR1 gene fusions implicated in endocrine therapy resistance of ER+ breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd6-4 |
0.517 |
|
| 2015 |
Iglesia MD, Vincent BG, Serody JS, Carey LA, Barry WT, Sikov WM, Hudis CA, Winer EM, Perou CM. Abstract PD1-2: Impact of tumor-infiltrating B-cell clonal diversity on response to neoadjuvant therapy in triple negative and HER2+ breast cancer treated on CALGB (Alliance) 40601 and 40603 Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Pd1-2 |
0.553 |
|
| 2015 |
Pei X, Bai F, Chan HL, Scott A, Smith MD, Fan C, Herschkowitz JI, Perou CM, Livingstone AS, Robbins DJ, Capobianco AJ. Abstract P4-05-01: Genetic analysis of the role of Brca1 in suppression of basal-like breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P4-05-01 |
0.81 |
|
| 2015 |
Han YJ, Zhang J, Prat A, Yoshimatsu T, Gomez-Vega M, Kwon J, Perou CM, Kannanganattu P, Olopade OI. Abstract LB-149: A novel strategy to inhibit CpG island hypermethylation and restore BRCA1 expression Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-149 |
0.483 |
|
| 2015 |
Walter V, Du Y, Yin X, Sun W, Wilkerson MD, Hayward MC, Salazar AH, Perou CM, Hayes DN. Abstract 4801: Integrated genomic analysis of chromosome 11 in squamous tumors Cancer Research. 75: 4801-4801. DOI: 10.1158/1538-7445.Am2015-4801 |
0.315 |
|
| 2015 |
Smith AM, Xiong J, Hunter L, Jordan J, Clark K, Darr DB, Norman S, Perou CM, Kim WY. Abstract 2649: Inhibition of mTOR, but not PI3K, is required for the anti-tumor efficacy in breast cancer of dual PI3K/mTOR inhibitors given in combination with MEK inhibitors Cancer Research. 75: 2649-2649. DOI: 10.1158/1538-7445.Am2015-2649 |
0.445 |
|
| 2015 |
Contreras CM, Silva GO, Pfefferle AD, Perou CM. Abstract 2307: Targeted agents and chemotherapeutic treatments of genetically engineered Basal-like breast cancer mouse model Cancer Research. 75: 2307-2307. DOI: 10.1158/1538-7445.Am2015-2307 |
0.53 |
|
| 2015 |
Darr D, Sharpless N, Perou C, Villena FPd, Miller D, Bendt K, Hursting SD. Abstract 2285: Germline genetic variation modulates tumor latency and response to therapy in a mouse model of basal-like breast cancer Cancer Research. 75: 2285-2285. DOI: 10.1158/1538-7445.Am2015-2285 |
0.525 |
|
| 2015 |
Zheng Z, Bu W, Tian L, Fan C, Gao X, Yu C, Jun L, Zhang X, Liao Y, Li Y, Lewis MT, Edwards D, Hilsenbeck SG, Medina D, Zwaka TP, ... Perou CM, et al. Abstract 2139: Wild type N-Ras, overexpressed in basal-like breast cancer, promotes tumor formation by inducing IL8 secretion via JAK2 activation Molecular and Cellular Biology. DOI: 10.1158/1538-7445.Am2015-2139 |
0.456 |
|
| 2015 |
Li H, Lan L, Drukker K, Perou C, Giger M. TU-AB-BRA-08: Radiomics in the Analysis of Breast Cancer Heterogeneity On DCE-MRI Medical Physics. 42: 3588-3588. DOI: 10.1118/1.4925513 |
0.55 |
|
| 2015 |
Mohammed H, Russell IA, Stark R, Rueda OM, Hickey TE, Tarulli GA, Serandour AAA, Birrell SN, Bruna A, Saadi A, Menon S, Hadfield J, Pugh M, Raj GV, Brown GD, ... ... Perou CM, et al. Progesterone receptor modulates ERα action in breast cancer Nature. 523: 313-317. DOI: 10.1038/nature14583 |
0.4 |
|
| 2014 |
Sun Z, Prat A, Cheang MCU, Gelber RD, Perou CM. Chemotherapy benefit for 'ER-positive' breast cancer and contamination of nonluminal subtypes—waiting for TAILORx and RxPONDER. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 26: 70-74. PMID 25355719 DOI: 10.1093/Annonc/Mdu493 |
0.504 |
|
| 2014 |
Bockhorn J, Prat A, Chang YF, Liu X, Huang S, Shang M, Nwachukwu C, Gomez-Vega MJ, Harrell JC, Olopade OI, Perou CM, Liu H. Differentiation and loss of malignant character of spontaneous pulmonary metastases in patient-derived breast cancer models. Cancer Research. 74: 7406-17. PMID 25339353 DOI: 10.1158/0008-5472.Can-14-1188 |
0.522 |
|
| 2014 |
Parra-Palau JL, Morancho B, Peg V, Escorihuela M, Scaltriti M, Vicario R, Zacarias-Fluck M, Pedersen K, Pandiella A, Nuciforo P, Serra V, Cortés J, Baselga J, Perou CM, Prat A, et al. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy. Journal of the National Cancer Institute. 106. PMID 25253614 DOI: 10.1093/Jnci/Dju291 |
0.483 |
|
| 2014 |
Bai F, Chan HL, Scott A, Smith MD, Fan C, Herschkowitz JI, Perou CM, Livingstone AS, Robbins DJ, Capobianco AJ, Pei XH. BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. Cancer Research. 74: 6161-72. PMID 25239453 DOI: 10.1158/0008-5472.Can-14-1119 |
0.792 |
|
| 2014 |
Song G, Darr DB, Santos CM, Ross M, Valdivia A, Jordan JL, Midkiff BR, Cohen S, Nikolaishvili-Feinberg N, Miller CR, Tarrant TK, Rogers AB, Dudley AC, Perou CM, Zamboni WC. Effects of tumor microenvironment heterogeneity on nanoparticle disposition and efficacy in breast cancer tumor models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6083-95. PMID 25231403 DOI: 10.1158/1078-0432.Ccr-14-0493 |
0.435 |
|
| 2014 |
Gatza ML, Silva GO, Parker JS, Fan C, Perou CM. An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nature Genetics. 46: 1051-9. PMID 25151356 DOI: 10.1038/Ng.3073 |
0.648 |
|
| 2014 |
Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, Muss HB. Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. The Oncologist. 19: 1076-83. PMID 25142841 DOI: 10.1634/Theoncologist.2014-0184 |
0.467 |
|
| 2014 |
Prat A, Carey LA, Adamo B, Vidal M, Tabernero J, Cortés J, Parker JS, Perou CM, Baselga J. Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. Journal of the National Cancer Institute. 106. PMID 25139534 DOI: 10.1093/Jnci/Dju152 |
0.715 |
|
| 2014 |
Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. How many etiological subtypes of breast cancer: two, three, four, or more? Journal of the National Cancer Institute. 106. PMID 25118203 DOI: 10.1093/Jnci/Dju165 |
0.56 |
|
| 2014 |
Hoadley KA, Yau C, Wolf DM, Cherniack AD, Tamborero D, Ng S, Leiserson MD, Niu B, McLellan MD, Uzunangelov V, Zhang J, Kandoth C, Akbani R, Shen H, Omberg L, ... ... Perou CM, et al. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 158: 929-44. PMID 25109877 DOI: 10.1016/J.Cell.2014.06.049 |
0.649 |
|
| 2014 |
Prat A, Lluch A, Albanell J, Barry WT, Fan C, Chacón JI, Parker JS, Calvo L, Plazaola A, Arcusa A, Seguí-Palmer MA, Burgues O, Ribelles N, Rodriguez-Lescure A, Guerrero A, ... ... Perou CM, et al. Predicting response and survival in chemotherapy-treated triple-negative breast cancer. British Journal of Cancer. 111: 1532-41. PMID 25101563 DOI: 10.1038/Bjc.2014.444 |
0.621 |
|
| 2014 |
Prat A, Cruz C, Hoadley KA, Díez O, Perou CM, Balmaña J. Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. Breast Cancer Research and Treatment. 147: 185-91. PMID 25048467 DOI: 10.1007/S10549-014-3056-X |
0.664 |
|
| 2014 |
Kimes PK, Cabanski CR, Wilkerson MD, Zhao N, Johnson AR, Perou CM, Makowski L, Maher CA, Liu Y, Marron JS, Hayes DN. SigFuge: single gene clustering of RNA-seq reveals differential isoform usage among cancer samples. Nucleic Acids Research. 42: e113. PMID 25030904 DOI: 10.1093/Nar/Gku521 |
0.403 |
|
| 2014 |
Anders C, Deal AM, Abramson V, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Kelly Marcom P, Van Poznak C, Stearns V, Melisko M, Smith JK, ... ... Perou CM, et al. TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. Breast Cancer Research and Treatment. 146: 557-66. PMID 25001612 DOI: 10.1007/S10549-014-3039-Y |
0.644 |
|
| 2014 |
Wilkerson MD, Cabanski CR, Sun W, Hoadley KA, Walter V, Mose LE, Troester MA, Hammerman PS, Parker JS, Perou CM, Hayes DN. Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. Nucleic Acids Research. 42: e107. PMID 24970867 DOI: 10.1093/Nar/Gku489 |
0.672 |
|
| 2014 |
Phillips S, Prat A, Sedic M, Proia T, Wronski A, Mazumdar S, Skibinski A, Shirley SH, Perou CM, Gill G, Gupta PB, Kuperwasser C. Cell-state transitions regulated by SLUG are critical for tissue regeneration and tumor initiation. Stem Cell Reports. 2: 633-47. PMID 24936451 DOI: 10.1016/J.Stemcr.2014.03.008 |
0.316 |
|
| 2014 |
Iglesia MD, Vincent BG, Parker JS, Hoadley KA, Carey LA, Perou CM, Serody JS. Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3818-29. PMID 24916698 DOI: 10.1158/1078-0432.Ccr-13-3368 |
0.763 |
|
| 2014 |
Mose LE, Wilkerson MD, Hayes DN, Perou CM, Parker JS. ABRA: improved coding indel detection via assembly-based realignment. Bioinformatics (Oxford, England). 30: 2813-5. PMID 24907369 DOI: 10.1093/Bioinformatics/Btu376 |
0.433 |
|
| 2014 |
Zhao W, He X, Hoadley KA, Parker JS, Hayes DN, Perou CM. Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. Bmc Genomics. 15: 419. PMID 24888378 DOI: 10.1186/1471-2164-15-419 |
0.628 |
|
| 2014 |
Tao JJ, Castel P, Radosevic-Robin N, Elkabets M, Auricchio N, Aceto N, Weitsman G, Barber P, Vojnovic B, Ellis H, Morse N, Viola-Villegas NT, Bosch A, Juric D, Hazra S, ... ... Perou CM, et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. Science Signaling. 7: ra29. PMID 24667376 DOI: 10.1126/Scisignal.2005125 |
0.379 |
|
| 2014 |
Drews-Elger K, Brinkman JA, Miller P, Shah SH, Harrell JC, da Silva TG, Ao Z, Schlater A, Azzam DJ, Diehl K, Thomas D, Slingerland JM, Perou CM, Lippman ME, El-Ashry D. Primary breast tumor-derived cellular models: characterization of tumorigenic, metastatic, and cancer-associated fibroblasts in dissociated tumor (DT) cultures. Breast Cancer Research and Treatment. 144: 503-17. PMID 24567196 DOI: 10.1007/S10549-014-2887-9 |
0.543 |
|
| 2014 |
Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, ... ... Perou C, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 384: 164-72. PMID 24529560 DOI: 10.1016/S0140-6736(13)62422-8 |
0.409 |
|
| 2014 |
Oh DS, Cheang MC, Fan C, Perou CM. Radiation-induced gene signature predicts pathologic complete response to neoadjuvant chemotherapy in breast cancer patients. Radiation Research. 181: 193-207. PMID 24527691 DOI: 10.1016/J.Ijrobp.2012.07.071 |
0.711 |
|
| 2014 |
Zhou B, Damrauer JS, Bailey ST, Hadzic T, Jeong Y, Clark K, Fan C, Murphy L, Lee CY, Troester MA, Miller CR, Jin J, Darr D, Perou CM, Levine RL, et al. Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. The Journal of Clinical Investigation. 124: 553-63. PMID 24435044 DOI: 10.1172/Jci69804 |
0.594 |
|
| 2014 |
Xiao L, Harrell JC, Perou CM, Dudley AC. Identification of a stable molecular signature in mammary tumor endothelial cells that persists in vitro. Angiogenesis. 17: 511-8. PMID 24257808 DOI: 10.1007/S10456-013-9409-Y |
0.373 |
|
| 2014 |
Nair R, Roden DL, Teo WS, McFarland A, Junankar S, Ye S, Nguyen A, Yang J, Nikolic I, Hui M, Morey A, Shah J, Pfefferle AD, Usary J, Selinger C, ... ... Perou CM, et al. c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. Oncogene. 33: 3992-4002. PMID 24056965 DOI: 10.1038/Onc.2013.368 |
0.79 |
|
| 2014 |
Harrell JC, Pfefferle AD, Zalles N, Prat A, Fan C, Khramtsov A, Olopade OI, Troester MA, Dudley AC, Perou CM. Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clinical & Experimental Metastasis. 31: 33-45. PMID 23975155 DOI: 10.1007/S10585-013-9607-4 |
0.535 |
|
| 2014 |
Romero A, Prat A, García-Sáenz JA, Del Prado N, Pelayo A, Furió V, Román JM, de la Hoya M, Díaz-Rubio E, Perou CM, Cladés T, Martín M. Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection. Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 16: 386-94. PMID 23907291 DOI: 10.1007/S12094-013-1088-Z |
0.487 |
|
| 2014 |
Mayer EL, Vaz-Luis I, Richardson AL, Perou CM, Tung NM, Abramson VG, Anders CK, Forero-Torres A, Marcom PK, Miller K, Puhalla S, Rimawi MF, Stearns V, Traina TA, Barry WT, et al. TBCRC030: A randomized, phase II study of preoperative cisplatin versus paclitaxel in patients (pts) with BRCA1/2-proficient triple-negative breast cancer (TNBC)—Evaluating the homologous recombination deficiency (HRD) biomarker. Journal of Clinical Oncology. 32: TPS1145-TPS1145. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps1145 |
0.406 |
|
| 2014 |
Miglarese MR, Wilkerson M, Fan C, Faruki H, Hayes DN, Perou CM, Lai-Goldman M. Evaluation of a lung cancer RNA expression subtyping panel and comparison with histologic diagnosis in lung tumor samples from multiple data sets including The Cancer Genome Atlas (TCGA). Journal of Clinical Oncology. 32: 7566-7566. DOI: 10.1200/Jco.2014.32.15_Suppl.7566 |
0.426 |
|
| 2014 |
Carey LA, Barry WT, Pitcher B, Hoadley KA, Cheang MCU, Anders CK, Henry NL, Tolaney SM, Dang CT, Krop IE, Harris L, Berry DA, Perou CM, Winer EP, Hudis CA. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). Journal of Clinical Oncology. 32: 506-506. DOI: 10.1200/Jco.2014.32.15_Suppl.506 |
0.717 |
|
| 2014 |
Cheang MCU, Perou CM, Whelan TJ, Fan C, Laurberg T, Voduc D, Tyldesley S, Nielsen T, Gelmon KA. Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature for locoregional relapse and long-term outcome. Journal of Clinical Oncology. 32: 1031-1031. DOI: 10.1200/Jco.2014.32.15_Suppl.1031 |
0.478 |
|
| 2014 |
D'Arcy ME, Robinson WR, Kirk E, Amos KD, Perou CM, Fleming JM, Troester MA. Abstract LB-292: Race-associated gene expression in tumors and breast cancer mortality disparities Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-292 |
0.577 |
|
| 2014 |
Young CD, Zimmerman LJ, Gatza ML, Morrison MM, Whitwell CA, Bhola NE, Hanker AB, Stricker T, Patel P, Brantley-Sieders DM, Perou CM, Park BH, Liebler DC, Cook RS, Arteaga CL. Abstract 970: Mass spectrometry analysis of PIK3CA mutant mammary epithelial cells identifies EGFR as a paracrine effector of PI3K in basal-like breast cancer Cancer Research. 74: 970-970. DOI: 10.1158/1538-7445.Am2014-970 |
0.503 |
|
| 2014 |
Walter V, Du Y, Yin X, Sun W, Wilkerson MD, Hayward MC, Salazar AH, Perou CM, Hayes DN. Abstract 5334: Integrated analysis of squamous tumors identifies novel targets and dissects gene regulation Cancer Research. 74: 5334-5334. DOI: 10.1158/1538-7445.Am2014-5334 |
0.42 |
|
| 2014 |
Darr D, Clark KS, Phillips JH, Pinheiro E, Sriram V, Xiong J, Jordan J, Sharpless NE, Perou C, Moschos S. Abstract 5024: mDX400, the murine analog against the anti-PD1 antibody MK-347 is active in immunocompetent, autochthonous murine models of melanoma and breast cancer Cancer Research. 74: 5024-5024. DOI: 10.1158/1538-7445.Am2014-5024 |
0.462 |
|
| 2014 |
Wolf DM, Fan C, Hoadley KA, Yau C, Sokolov A, Stuart J, Perou C, Veer Lv'. Abstract 360: Thousands of published cancer signatures and pathways can be collapsed into a handful of non-redundant gene programs: a TCGA pan-cancer analysis Cancer Research. 74: 360-360. DOI: 10.1158/1538-7445.Am2014-360 |
0.652 |
|
| 2014 |
Anderson WF, Rosenberg PS, Prat A, Perou CM, Sherman ME. Abstract 266: How many epidemiological types of breast cancer: Two, three, four, or more Cancer Research. 74: 266-266. DOI: 10.1158/1538-7445.Am2014-266 |
0.575 |
|
| 2014 |
Tobin N, Harrell J, Egyhazi Brage S, Frostvik Stolt M, Perou C, Bergh J, Hatschek T, Lindström L. Molecular Subtype of Breast Cancer Metastases Significantly Influences Patient Post-Relapse Survival Annals of Oncology. 25: i5. DOI: 10.1093/Annonc/Mdu065.1 |
0.526 |
|
| 2014 |
Morancho B, Parra-Palau J, Peg V, Vicario R, Zacarias-Fluck M, Pedersen K, Perou C, Prat A, Rubio I, Arribas J. 306: Chemotherapy sensitizes p95HER2-positive breast cancers to trastuzumab European Journal of Cancer. 50: S72-S73. DOI: 10.1016/S0959-8049(14)50272-9 |
0.44 |
|
| 2014 |
Singh N, Couture HD, Marron JS, Perou C, Niethammer M. Topological descriptors of histology images Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 8679: 231-239. |
0.35 |
|
| 2013 |
Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus MI, Brown M, Egan SE, Wahl GM, Rosen JM, Perou CM. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biology. 14: R125. PMID 24220145 DOI: 10.1186/Gb-2013-14-11-R125 |
0.784 |
|
| 2013 |
Sundaram S, Freemerman AJ, Johnson AR, Milner JJ, McNaughton KK, Galanko JA, Bendt KM, Darr DB, Perou CM, Troester MA, Makowski L. Role of HGF in obesity-associated tumorigenesis: C3(1)-TAg mice as a model for human basal-like breast cancer. Breast Cancer Research and Treatment. 142: 489-503. PMID 24218051 DOI: 10.1007/S10549-013-2741-5 |
0.35 |
|
| 2013 |
Bardowell SA, Parker J, Fan C, Crandell J, Perou CM, Swift-Scanlan T. Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. Breast Cancer Research and Treatment. 142: 365-80. PMID 24212716 DOI: 10.1007/S10549-013-2738-0 |
0.654 |
|
| 2013 |
Prat A, Karginova O, Parker JS, Fan C, He X, Bixby L, Harrell JC, Roman E, Adamo B, Troester M, Perou CM. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Research and Treatment. 142: 237-55. PMID 24162158 DOI: 10.1158/1538-7445.Am2011-3328 |
0.652 |
|
| 2013 |
Brennan CW, Verhaak RG, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhim R, Bernard B, Wu CJ, Genovese G, Shmulevich I, ... ... Perou CM, et al. The somatic genomic landscape of glioblastoma. Cell. 155: 462-77. PMID 24120142 DOI: 10.1016/J.Cell.2013.09.034 |
0.431 |
|
| 2013 |
Ciriello G, Sinha R, Hoadley KA, Jacobsen AS, Reva B, Perou CM, Sander C, Schultz N. The molecular diversity of Luminal A breast tumors. Breast Cancer Research and Treatment. 141: 409-20. PMID 24096568 DOI: 10.1007/S10549-013-2699-3 |
0.717 |
|
| 2013 |
Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, Ding L, Griffith OL, Miller C, Larson D, Fulton RS, ... ... Perou CM, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Reports. 4: 1116-30. PMID 24055055 DOI: 10.1016/J.Celrep.2013.08.022 |
0.491 |
|
| 2013 |
Morrison MM, Hutchinson K, Williams MM, Stanford JC, Balko JM, Young C, Kuba MG, Sánchez V, Williams AJ, Hicks DJ, Arteaga CL, Prat A, Perou CM, Earp HS, Massarweh S, et al. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens. The Journal of Clinical Investigation. 123: 4329-43. PMID 23999432 DOI: 10.1172/Jci66764 |
0.595 |
|
| 2013 |
Chen K, Navin NE, Wang Y, Schmidt HK, Wallis JW, Niu B, Fan X, Zhao H, McLellan MD, Hoadley KA, Mardis ER, Ley TJ, Perou CM, Wilson RK, Ding L. BreakTrans: uncovering the genomic architecture of gene fusions. Genome Biology. 14: R87. PMID 23972288 DOI: 10.1186/Gb-2013-14-8-R87 |
0.677 |
|
| 2013 |
Hanker AB, Pfefferle AD, Balko JM, Kuba MG, Young CD, Sánchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. Proceedings of the National Academy of Sciences of the United States of America. 110: 14372-7. PMID 23940356 DOI: 10.1073/Pnas.1303204110 |
0.578 |
|
| 2013 |
Cabanski CR, Wilkerson MD, Soloway M, Parker JS, Liu J, Prins JF, Marron JS, Perou CM, Hayes DN. BlackOPs: increasing confidence in variant detection through mappability filtering. Nucleic Acids Research. 41: e178. PMID 23935067 DOI: 10.1093/Nar/Gkt692 |
0.479 |
|
| 2013 |
Richards KL, Motsinger-Reif AA, Chen HW, Fedoriw Y, Fan C, Nielsen DM, Small GW, Thomas R, Smith C, Dave SS, Perou CM, Breen M, Borst LB, Suter SE. Gene profiling of canine B-cell lymphoma reveals germinal center and postgerminal center subtypes with different survival times, modeling human DLBCL. Cancer Research. 73: 5029-39. PMID 23783577 DOI: 10.1158/0008-5472.Can-12-3546 |
0.376 |
|
| 2013 |
Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, Prat A, Cheang MC, Herschkowitz JI, Rosen JM, Zamboni W, ... ... Perou CM, et al. Predicting drug responsiveness in human cancers using genetically engineered mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4889-99. PMID 23780888 DOI: 10.1158/1078-0432.Ccr-13-0522 |
0.776 |
|
| 2013 |
Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, Wong H, Fuqua SW, Contreras A, Gutierrez C, Huang J, ... ... Perou CM, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Research. 73: 4885-97. PMID 23737486 DOI: 10.1158/0008-5472.Can-12-4081 |
0.526 |
|
| 2013 |
Jordan NV, Prat A, Abell AN, Zawistowski JS, Sciaky N, Karginova OA, Zhou B, Golitz BT, Perou CM, Johnson GL. SWI/SNF chromatin-remodeling factor Smarcd3/Baf60c controls epithelial-mesenchymal transition by inducing Wnt5a signaling. Molecular and Cellular Biology. 33: 3011-25. PMID 23716599 DOI: 10.1128/Mcb.01443-12 |
0.504 |
|
| 2013 |
Won JR, Gao D, Chow C, Cheng J, Lau SY, Ellis MJ, Perou CM, Bernard PS, Nielsen TO. A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. 26: 1438-50. PMID 23702728 DOI: 10.1038/Modpathol.2013.97 |
0.588 |
|
| 2013 |
Wilkerson MD, Schallheim JM, Hayes DN, Roberts PJ, Bastien RR, Mullins M, Yin X, Miller CR, Thorne LB, Geiersbach KB, Muldrew KL, Funkhouser WK, Fan C, Hayward MC, Bayer S, ... Perou CM, et al. Prediction of lung cancer histological types by RT-qPCR gene expression in FFPE specimens. The Journal of Molecular Diagnostics : Jmd. 15: 485-97. PMID 23701907 DOI: 10.1016/J.Jmoldx.2013.03.007 |
0.447 |
|
| 2013 |
Anders CK, Adamo B, Karginova O, Deal AM, Rawal S, Darr D, Schorzman A, Santos C, Bash R, Kafri T, Carey L, Miller CR, Perou CM, Sharpless N, Zamboni WC. Pharmacokinetics and efficacy of PEGylated liposomal doxorubicin in an intracranial model of breast cancer. Plos One. 8: e61359. PMID 23650496 DOI: 10.1371/Journal.Pone.0061359 |
0.409 |
|
| 2013 |
Young CD, Pfefferle AD, Owens P, Kuba MG, Rexer BN, Balko JM, Sánchez V, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. Cancer Research. 73: 4075-85. PMID 23633485 DOI: 10.1158/0008-5472.Can-12-4579 |
0.48 |
|
| 2013 |
MartÃn M, Prat A, RodrÃguez-Lescure A, Caballero R, Ebbert MT, Munárriz B, Ruiz-Borrego M, Bastien RR, Crespo C, Davis C, RodrÃguez CA, López-Vega JM, Furió V, GarcÃa AM, Casas M, ... ... Perou CM, et al. PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Research and Treatment. 138: 457-66. PMID 23423445 DOI: 10.1007/S10549-013-2416-2 |
0.429 |
|
| 2013 |
Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. The Oncologist. 18: 123-33. PMID 23404817 DOI: 10.1634/Theoncologist.2012-0397 |
0.613 |
|
| 2013 |
Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM, Miller CR, et al. Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nature Communications. 4: 1449. PMID 23385593 DOI: 10.1038/Ncomms2438 |
0.562 |
|
| 2013 |
Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang YF, Huo D, Wen Y, Swanson KE, Qiu T, Lu J, Young Park S, Eileen Dolan M, Perou CM, et al. MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11 Nature Communications. 4. PMID 23340433 DOI: 10.1038/Ncomms2393 |
0.496 |
|
| 2013 |
Nguyen DH, Fredlund E, Zhao W, Perou CM, Balmain A, Mao JH, Barcellos-Hoff MH. Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1353-62. PMID 23339125 DOI: 10.1158/1078-0432.Ccr-12-3554 |
0.501 |
|
| 2013 |
Ellis MJ, Perou CM. The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discovery. 3: 27-34. PMID 23319768 DOI: 10.1158/2159-8290.Cd-12-0462 |
0.558 |
|
| 2013 |
Ulirsch J, Fan C, Knafl G, Wu MJ, Coleman B, Perou CM, Swift-Scanlan T. Vimentin DNA methylation predicts survival in breast cancer. Breast Cancer Research and Treatment. 137: 383-96. PMID 23239149 DOI: 10.1007/S10549-012-2353-5 |
0.595 |
|
| 2013 |
Brauer HA, Makowski L, Hoadley KA, Casbas-Hernandez P, Lang LJ, Romàn-Pèrez E, D'Arcy M, Freemerman AJ, Perou CM, Troester MA. Impact of tumor microenvironment and epithelial phenotypes on metabolism in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 571-85. PMID 23236214 DOI: 10.1158/1078-0432.Ccr-12-2123 |
0.684 |
|
| 2013 |
Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM. Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 203-9. PMID 23233704 DOI: 10.1200/Jco.2012.43.4134 |
0.698 |
|
| 2013 |
Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olopade OI, Clarke MF, Greene GL, Liu H. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion Breast Cancer Research and Treatment. 137: 373-382. PMID 23224145 DOI: 10.1007/S10549-012-2346-4 |
0.533 |
|
| 2013 |
Wilkerson M, Lai-Goldman M, Bernard PS, Perou CM, Hayes DN, Grilley-Olson JE. Reproducible molecular characterization of non-small cell lung cancer from paraffin. Journal of Clinical Oncology. 31: 7576-7576. DOI: 10.1200/Jco.2013.31.15_Suppl.7576 |
0.351 |
|
| 2013 |
Anders CK, Deal AM, Abramson VG, Liu MC, Storniolo AM, Carpenter JT, Puhalla S, Nanda R, Melhem-Bertrandt A, Lin NU, Marcom PK, Poznak CHV, Stearns V, Melisko ME, Smith JK, ... ... Perou CM, et al. TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) central nervous system (CNS) metastases (mets). Journal of Clinical Oncology. 31: 515-515. DOI: 10.1200/Jco.2013.31.15_Suppl.515 |
0.374 |
|
| 2013 |
Johnson GL, Amos KD, Duncan JS, Whittle M, Zawistowki J, Goulet D, He X, Noe J, Perou CM, Earp S, Carey LA. Kinome reprogramming response to MEK inhibition: A window-of-opportunity trial in triple-negative breast cancer (TNBC). Journal of Clinical Oncology. 31: 512-512. DOI: 10.1200/Jco.2013.31.15_Suppl.512 |
0.427 |
|
| 2013 |
Carey LA, Berry DA, Ollila D, Harris L, Krop IE, Weckstein D, Henry NL, Anders CK, Cirrincione C, Winer EP, Perou CM, Hudis C, Alliance. Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. Journal of Clinical Oncology. 31: 500-500. DOI: 10.1200/Jco.2013.31.15_Suppl.500 |
0.531 |
|
| 2013 |
Grushko TA, Gomez-Vega MJ, Prat A, Mueller J, Coyle M, Perou CM, Guindalini RSC, Obeid E, Irie H, Olopade OI. Protein tyrosine kinase 6 (PTK6, BRK) amplification in HER2+ breast cancer as a mechanism of HER2 resistance. Journal of Clinical Oncology. 31: 11021-11021. DOI: 10.1200/Jco.2013.31.15_Suppl.11021 |
0.63 |
|
| 2013 |
Herschkowitz JI, Coarfa C, Prat A, Toneff MJ, Hoadley KA, Dinger ME, Mattick JS, Mani SA, Perou CM, Rosen JM. Abstract A039: The role of long noncoding RNAs in epithelial to mesenchymal transition and cancer stem cells Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A039 |
0.679 |
|
| 2013 |
Harrell JC, Pfefferle A, Zalles N, Prat A, Fan C, Khramtsov A, Olopade O, Troester M, Dudley A, Perou C. Abstract A027: Endothelial-like properties of triple-negative claudin-low breast cancer cells promote tumor-vascular interactions and tumor permeability Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A027 |
0.529 |
|
| 2013 |
Hanker AB, Pfefferle A, Balko JM, Kuba MG, Young CD, Sanchez V, Sutton CR, Cheng H, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Abstract A007: Mutant PIK3CA accelerates HER2-driven transgenic mammary tumor progression, enhances cancer stem cell features, and induces resistance to combinations of anti-HER2 therapies Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-A007 |
0.584 |
|
| 2013 |
Hoadley KA, Fan C, Wilkerson MD, Mose LE, Jefferys SR, Auman JT, Parker JS, Hayes DN, Perou CM. Abstract SY12-03: Multi-tumor analysis of TCGA data identifies expression commonalities across tumor types. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Sy12-03 |
0.721 |
|
| 2013 |
Perou CM. Abstract PL01-03: The therapeutic implications of genome sequencing and expression analyses for breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Pl01-03 |
0.599 |
|
| 2013 |
Ellis MJ, Li S, Shen D, Ding L, Crowder R, Shao J, Goncalves R, Tao Y, Luo J, Prat A, Liu W, Gonzalez-Angulo AM, Liu S, McMichael JF, Miller C, ... ... Perou C, et al. Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-265 |
0.555 |
|
| 2013 |
Li S, Shen D, Li D, Yu T, Luo J, Hoog J, McMichael J, Miller C, Larson D, Bose R, Fulton B, Wilson R, Perou C, Mardis E, Ellis M. Abstract LB-236: Patient derived xenografts as high-fidelity genomic models for advanced breast cancer. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-236 |
0.522 |
|
| 2013 |
Liu H, Bockhorn J, Dalton R, Nwachukwu C, Huang S, Prat A, Yee K, Chang Y, Huo D, Lu J, Dolan E, Perou CM, Olopade OI, Clarke MF, Greene G. Abstract 832: MicroRNA-30c inhibits human breast tumor chemo-resistance by regulating twinfinlin-1 (TWF1) and IL-11. Cancer Research. 73: 832-832. DOI: 10.1158/1538-7445.Am2013-832 |
0.458 |
|
| 2013 |
Giovanni C, Perou CM, Sander C, Schultz N. Abstract 822: The molecular diversity of Luminal A breast cancer. Cancer Research. 73: 822-822. DOI: 10.1158/1538-7445.Am2013-822 |
0.56 |
|
| 2013 |
Bockhorn J, Yee K, Chang Y, Prat A, Huo D, Nwachukwu C, Dalton R, Huang S, Swanson KE, Perou CM, Olufunmilayo OI, Clarke MF, Liu H, Greene G. Abstract 5337: MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Cancer Research. 73: 5337-5337. DOI: 10.1158/1538-7445.Am2013-5337 |
0.535 |
|
| 2013 |
Song G, Darr DB, Santos CM, White TF, Jordan JL, Kim M, Midkiff BR, Feinberg NN, Miller R, Rogers AB, Dudley AC, Perou CM, Zamboni WC. Abstract 3354: Relationship between tumor-associated macrophages (TAMs), tumor delivery, and efficacy of PEGylated liposomal doxorubicin (PLD) and non-liposomal doxorubicin (NL-doxo) in genetically engineered mouse models (GEMMs) of breast cancer (BC). Cancer Research. 73: 3354-3354. DOI: 10.1158/1538-7445.Am2013-3354 |
0.388 |
|
| 2013 |
Gatza M, Silva G, Hoadley K, Fan C, Perou C. Abstract S4-01: An integrated genomics approach identifies novel drivers of oncogenic pathway activity in human breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-S4-01 |
0.729 |
|
| 2013 |
Chen Y, Allison K, Lester S, Collins L, Eberhard D, Factor R, Jensen K, Johnson N, Korski K, Reis-Filho J, Sanders M, Shin S, Tan P, Tse G, Waldman F, ... ... Perou C, et al. Abstract P4-05-15: Breast cancers with BRCA1 and BRCA2 mutations are associated with specific pathologic features and molecular profiles: Results from a TCGA sub-analysis Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-05-15 |
0.442 |
|
| 2013 |
Sanders M, Allison K, Chen Y, Lester S, Johnson N, Factor R, Tse G, Shin S, Eberhard D, Tan P, Perou C, Collins L, Jensen K, Korski K, Waldman F, et al. Abstract P4-05-10: PIK3CA mutations are enriched in invasive lobular carcinomas and invasive mammary carcinomas with lobular features: Results from a TCGA sub-analysis Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-05-10 |
0.397 |
|
| 2013 |
Allison K, Chen Y, Jensen K, Sanders M, Reis-Filho J, Lester S, Johnson N, Factor R, Tse G, Shin S, Eberhard D, Tan P, Collins L, Korski K, Waldman F, ... Perou C, et al. Abstract P4-05-06: Host inflammation and breast cancer molecular subtypes: Updated results from a TCGA sub-analysis Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-P4-05-06 |
0.527 |
|
| 2013 |
Overmoyer B, Regan M, Brugge J, Perou C, Nakhlis F, Jennifer B, Heather J, Eren Y, Judith H, Winer E. Abstract OT1-1-07: Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory breast cancer Cancer Research. 73. DOI: 10.1158/0008-5472.Sabcs13-Ot1-1-07 |
0.45 |
|
| 2012 |
Smith BA, Shelton DN, Kieffer C, Milash B, Usary J, Perou CM, Bernard PS, Welm BE. Targeting the PyMT Oncogene to Diverse Mammary Cell Populations Enhances Tumor Heterogeneity and Generates Rare Breast Cancer Subtypes. Genes & Cancer. 3: 550-63. PMID 23486760 DOI: 10.1177/1947601913475359 |
0.599 |
|
| 2012 |
Chao HH, He X, Parker JS, Zhao W, Perou CM. Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. Plos One. 7: e51719. PMID 23284754 DOI: 10.1371/Journal.Pone.0051719 |
0.766 |
|
| 2012 |
Bastien RR, RodrÃguez-Lescure Ã, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Ãlvarez I, Dowell T, Wall D, Seguà MÃ, Barley L, ... ... Perou CM, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. Bmc Medical Genomics. 5: 44. PMID 23035882 DOI: 10.1186/1755-8794-5-44 |
0.578 |
|
| 2012 |
Cabanski CR, Cavin K, Bizon C, Wilkerson MD, Parker JS, Wilhelmsen KC, Perou CM, Marron JS, Hayes DN. ReQON: a Bioconductor package for recalibrating quality scores from next-generation sequencing data. Bmc Bioinformatics. 13: 221. PMID 22946927 DOI: 10.1186/1471-2105-13-221 |
0.442 |
|
| 2012 |
Roberts PJ, Usary JE, Darr DB, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest AJ, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 5290-303. PMID 22872574 DOI: 10.1158/1078-0432.Ccr-12-0563 |
0.527 |
|
| 2012 |
Wallace MD, Pfefferle AD, Shen L, McNairn AJ, Cerami EG, Fallon BL, Rinaldi VD, Southard TL, Perou CM, Schimenti JC. Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. Genetics. 192: 385-96. PMID 22851646 DOI: 10.1534/Genetics.112.142802 |
0.577 |
|
| 2012 |
Prat A, Parker JS, Fan C, Perou CM. PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer. Breast Cancer Research and Treatment. 135: 301-6. PMID 22752290 DOI: 10.1007/S10549-012-2143-0 |
0.664 |
|
| 2012 |
Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, Mardis E, Leung S, Ung K, Pritchard KI, Parker JS, Bernard PS, Perou CM, Ellis MJ, Nielsen TO. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4465-72. PMID 22711706 DOI: 10.1158/1078-0432.Ccr-12-0286 |
0.633 |
|
| 2012 |
Liu W, Monahan KB, Pfefferle AD, Shimamura T, Sorrentino J, Chan KT, Roadcap DW, Ollila DW, Thomas NE, Castrillon DH, Miller CR, Perou CM, Wong KK, Bear JE, Sharpless NE. LKB1/STK11 inactivation leads to expansion of a prometastatic tumor subpopulation in melanoma. Cancer Cell. 21: 751-64. PMID 22698401 DOI: 10.1016/J.Ccr.2012.03.048 |
0.334 |
|
| 2012 |
Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, Wolff AC, Hobday TJ, Ivanova A, Chiu WK, Ferraro M, ... ... Perou CM, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2615-23. PMID 22665533 DOI: 10.1200/Jco.2010.34.5579 |
0.658 |
|
| 2012 |
Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 3242-9. PMID 22649152 DOI: 10.1200/Jco.2011.39.2779 |
0.518 |
|
| 2012 |
Xu K, Usary J, Kousis PC, Prat A, Wang DY, Adams JR, Wang W, Loch AJ, Deng T, Zhao W, Cardiff RD, Yoon K, Gaiano N, Ling V, Beyene J, ... ... Perou CM, et al. Lunatic fringe deficiency cooperates with the Met/Caveolin gene amplicon to induce basal-like breast cancer. Cancer Cell. 21: 626-41. PMID 22624713 DOI: 10.1016/J.Ccr.2012.03.041 |
0.504 |
|
| 2012 |
Wilkerson MD, Yin X, Walter V, Zhao N, Cabanski CR, Hayward MC, Miller CR, Socinski MA, Parsons AM, Thorne LB, Haithcock BE, Veeramachaneni NK, Funkhouser WK, Randell SH, Bernard PS, ... Perou CM, et al. Differential pathogenesis of lung adenocarcinoma subtypes involving sequence mutations, copy number, chromosomal instability, and methylation. Plos One. 7: e36530. PMID 22590557 DOI: 10.1371/Journal.Pone.0036530 |
0.406 |
|
| 2012 |
Dunlap SM, Chiao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, Hursting SD. Dietary energy balance modulates epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. Cancer Prevention Research (Philadelphia, Pa.). 5: 930-42. PMID 22588949 DOI: 10.1158/1940-6207.Capr-12-0034 |
0.499 |
|
| 2012 |
Hutti JE, Pfefferle AD, Russell SC, Sircar M, Perou CM, Baldwin AS. Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. Cancer Research. 72: 3260-9. PMID 22552288 DOI: 10.1158/0008-5472.Can-11-4141 |
0.393 |
|
| 2012 |
Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 23: 2866-73. PMID 22532584 DOI: 10.1200/Jco.2011.29.15_Suppl.502 |
0.664 |
|
| 2012 |
Duncan JS, Whittle MC, Nakamura K, Abell AN, Midland AA, Zawistowski JS, Johnson NL, Granger DA, Jordan NV, Darr DB, Usary J, Kuan PF, Smalley DM, Major B, He X, ... ... Perou CM, et al. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell. 149: 307-21. PMID 22500798 DOI: 10.1016/J.Cell.2012.02.053 |
0.632 |
|
| 2012 |
Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, Schultz N, Du Y, Zhang Y, Larsson E, Sheridan R, Xiao W, Spellman PT, Getz G, Wheeler DA, Perou CM, et al. Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. Plos One. 7: e34546. PMID 22479643 DOI: 10.1371/Journal.Pone.0034546 |
0.319 |
|
| 2012 |
Cheang MC, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Davies S, Stijleman IJ, Davis C, Ebbert MT, Parker JS, Ellis MJ, ... ... Perou CM, et al. Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2402-12. PMID 22351696 DOI: 10.1158/1078-0432.Ccr-11-2956 |
0.651 |
|
| 2012 |
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Research and Treatment. 132: 1049-62. PMID 22198468 DOI: 10.1007/S10549-011-1895-2 |
0.536 |
|
| 2012 |
Balko JM, Miller TW, Morrison MM, Hutchinson K, Young C, Rinehart C, Sánchez V, Jee D, Polyak K, Prat A, Perou CM, Arteaga CL, Cook RS. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proceedings of the National Academy of Sciences of the United States of America. 109: 221-6. PMID 22178756 DOI: 10.1073/Pnas.1115802109 |
0.398 |
|
| 2012 |
Prat A, Ellis MJ, Perou CM. Practical implications of gene-expression-based assays for breast oncologists. Nature Reviews. Clinical Oncology. 9: 48-57. PMID 22143140 DOI: 10.1038/Nrclinonc.2011.178 |
0.563 |
|
| 2012 |
Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Børresen-Dale AL, Olopade OI, Perou CM. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Research and Treatment. 133: 865-80. PMID 22048815 DOI: 10.1007/S10549-011-1846-Y |
0.782 |
|
| 2012 |
Haughian JM, Pinto MP, Harrell JC, Bliesner BS, Joensuu KM, Dye WW, Sartorius CA, Tan AC, Heikkilä P, Perou CM, Horwitz KB. Maintenance of hormone responsiveness in luminal breast cancers by suppression of Notch. Proceedings of the National Academy of Sciences of the United States of America. 109: 2742-7. PMID 21969591 DOI: 10.1073/Pnas.1106509108 |
0.517 |
|
| 2012 |
Keller PJ, Arendt LM, Skibinski A, Logvinenko T, Klebba I, Dong S, Smith AE, Prat A, Perou CM, Gilmore H, Schnitt S, Naber SP, Garlick JA, Kuperwasser C. Defining the cellular precursors to human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 109: 2772-7. PMID 21940501 DOI: 10.1073/Pnas.1017626108 |
0.587 |
|
| 2012 |
Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, Sørlie T, Wärnberg F, Haakensen VD, Helland Å, Naume B, Perou CM, Haussler D, Troyanskaya OG, Børresen-Dale AL. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proceedings of the National Academy of Sciences of the United States of America. 109: 2802-7. PMID 21908711 DOI: 10.1073/Pnas.1108781108 |
0.558 |
|
| 2012 |
Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, Anders C, Ewend M, Perou CM. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Research and Treatment. 132: 523-35. PMID 21671017 DOI: 10.1007/S10549-011-1619-7 |
0.602 |
|
| 2012 |
Herschkowitz JI, Zhao W, Zhang M, Usary J, Murrow G, Edwards D, Knezevic J, Greene SB, Darr D, Troester MA, Hilsenbeck SG, Medina D, Perou CM, Rosen JM. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proceedings of the National Academy of Sciences of the United States of America. 109: 2778-83. PMID 21633010 DOI: 10.1073/Pnas.1018862108 |
0.77 |
|
| 2012 |
Glück S, Ross JS, Royce M, McKenna EF, Perou CM, Avisar E, Wu L. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab. Breast Cancer Research and Treatment. 132: 781-91. PMID 21373875 DOI: 10.1007/S10549-011-1412-7 |
0.492 |
|
| 2012 |
Jenkins EO, Deal AM, Anders CK, Prat A, Perou CM, Carey LA, Muss HB. Breast cancer intrinsic subtypes by PAM50 in older women. Journal of Clinical Oncology. 30: 1524-1524. DOI: 10.1200/Jco.2012.30.15_Suppl.1524 |
0.459 |
|
| 2012 |
Prat A, Lluch A, Albanell J, Fang C, Lopez-Muniz JIC, Parker JS, Calvo L, Plazaola A, Lanza AA, Seguí-Palmer MA, Burgues O, Vicioso L, Sanchez-Simon R, Bermejo B, Ribelles N, ... ... Perou CM, et al. Gene expression-based predictors of chemotherapy response in basal-like breast cancer. Journal of Clinical Oncology. 30: 10500-10500. DOI: 10.1200/Jco.2012.30.15_Suppl.10500 |
0.667 |
|
| 2012 |
Willis S, Miller K, Young BF, Perou CM, Hu Z, Sparano J, Gray RJ, Sledge GW, Davidson NE, Leyland-Jones B. Association of a compact 13-gene VEGF signature with OS in E2100. Journal of Clinical Oncology. 30: 1027-1027. DOI: 10.1200/Jco.2012.30.15_Suppl.1027 |
0.425 |
|
| 2012 |
Cheang MCU, Martin M, Nielsen TO, Prat A, Rodriguez-Lescure A, Ruiz A, Chia SKL, Shepherd LE, Voduc D, Bernard PS, Ellis MJ, Perou CM, Leo AD, Carey LA. Quantitative hormone receptors, triple-negative breast cancer (TNBC), and molecular subtypes: A collaborative effort of the BIG-NCI NABCG. Journal of Clinical Oncology. 30: 1008-1008. DOI: 10.1200/Jco.2012.30.15_Suppl.1008 |
0.478 |
|
| 2012 |
Brauer HA, Makowski L, Hoadley KA, Lang LJ, Freemerman AJ, Perou CM, Troester MA. Impact of stromal microenvironment on metabolic phenotypes in breast cancer: evidence for stroma-influenced Warburg effect Bmc Proceedings. 6. DOI: 10.1186/1753-6561-6-S3-P8 |
0.671 |
|
| 2012 |
Young CD, Kuba MG, Owens P, Balko JM, Pfefferle A, Sanchez V, Perou CM, Zhao JJ, Cook RS, Arteaga CL. Abstract LB-103: Conditional loss of ErbB3 delays mammary gland hyperplasias induced by mutant PIK3CA in transgenic mice, but does not affect mammary tumor latency, gene expression or signaling Cancer Research. 72. DOI: 10.1158/1538-7445.Am2012-Lb-103 |
0.502 |
|
| 2012 |
Hutti J, Pfefferle A, Perou C, Baldwin A. Abstract 988: Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation Cancer Research. 72: 988-988. DOI: 10.1158/1538-7445.Am2012-988 |
0.434 |
|
| 2012 |
Hanker AB, Kuba MG, Sanchez V, Sutton CR, Pfefferle A, Balko JM, Perou CM, Cook RS, Arteaga CL. Abstract 4875: Human HER2 and PI3K H1047R cooperate to promote mammary tumorigenesis in vivo Cancer Research. 72: 4875-4875. DOI: 10.1158/1538-7445.Am2012-4875 |
0.315 |
|
| 2012 |
Nguyen DH, Fredlund E, Zhao W, Perou CM, Balmain A, Mao J, Barcellos-Hoff MH. Abstract 4268: Gene signature of host irradiation from Trp53 null mammary tumors detects radiation-preceded human cancers and has prognostic value for sporadic human breast cancer Cancer Research. 72: 4268-4268. DOI: 10.1158/1538-7445.Am2012-4268 |
0.57 |
|
| 2012 |
Liu H, Bockhorn J, Dalton R, Nwachukwu C, Prat A, Yee K, Huang S, Swanson K, Perou CM, Olopade OI, Clarke MF, Greene GL. Abstract 3331: MicroRNAs regulate breast cancer stem cells and spontaneous metastases in orthotopic xenograft models Cancer Research. 72: 3331-3331. DOI: 10.1158/1538-7445.Am2012-3331 |
0.493 |
|
| 2012 |
Han YJ, Prat A, Osborne RA, Perou CM, Olopade OI. Abstract 200: A transcribed BRCA1 pseudogene regulates gene expression and promotes breast cancer cell proliferation. Cancer Research. 72: 200-200. DOI: 10.1158/1538-7445.Am2012-200 |
0.548 |
|
| 2012 |
Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Zujewski J, Justice R, Loibl S, Wickerham L, Bogaerts J, ... ... Perou C, et al. Abstract S1-11: Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-S1-11 |
0.512 |
|
| 2012 |
Bargiacchi F, Earp H, Perou C. Abstract P6-03-01: Molecular Dissection of Breast Luminal Cell Transcription Factor Networks Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-03-01 |
0.457 |
|
| 2012 |
Sundaram S, Freemerman A, Hamilton J, McNaughton K, Galanko J, Darr D, Perou C, Troester M, Makowski L. Abstract P6-02-09: Role of HGF in obesity-associated tumorigenesis: C3(1)-Tag mice as a model for human basal-like breast cancer Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P6-02-09 |
0.393 |
|
| 2012 |
Cook R, Morrison M, Arteaga C, Perou C. Abstract P5-19-01: Targeting the HER3-phosphatidyl inositol-3 kinase pathway in breast cancers Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P5-19-01 |
0.608 |
|
| 2012 |
Cortazar P, Zhang L, Untch M, Mehta K, Costantino J, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Zujewski JA, Justice R, Loibl S, Wickerham L, Bogaerts J, ... ... Perou C, et al. Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) Cancer Research. 72. DOI: 10.1158/0008-5472.Sabcs12-P1-14-20 |
0.513 |
|
| 2012 |
Haakensen V, Lüders T, Riis M, Prat A, Perou C, Kristensen V, Børresen-Dale A, Helland A. 163 A Subtype of Gene Expression with Claudin-low Features in Normal Breast Tissue and in Fibroadenomas European Journal of Cancer. 48: S87. DOI: 10.1016/S0959-8049(12)70231-9 |
0.368 |
|
| 2012 |
Prat A, Cheang MC, Martín M, Carrasco E, Caballero R, Tyldesley S, Gelmon K, Bernard PS, Nielsen TO, Perou CM. 10O_PR Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically-Defined Luminal A Breast Cancer Annals of Oncology. 23. DOI: 10.1016/S0923-7534(19)65682-6 |
0.552 |
|
| 2011 |
Adamo B, Deal AM, Livasy C, Burrows E, Fritchie K, Blackwell KL, Hamilton EP, Geradts J, Thorne L, Ugolkov A, Miller CR, Ewend MG, Carey LA, Perou CM, Cryns VL, et al. AlphaB-crystallin (aBC) expression in breast cancer brain metastases (BM) and primary breast cancer (pBC) with eventual BM and association with outcome. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2041. PMID 28023795 DOI: 10.1200/Jco.2011.29.15_Suppl.2041 |
0.509 |
|
| 2011 |
Anders CK, Nanda R, Liu MC, Blackwell KL, Van Poznak CH, Abramson VG, Storniolo AM, Lin NU, Stearns V, Melhem A, Puhalla S, Carpenter JT, Melisko ME, Deal AM, Hudis C, ... ... Perou CM, et al. TBCRC 018: Phase II study of iniparib plus chemotherapy to treat triple-negative breast cancer (TNBC) brain metastases (BM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: TPS127. PMID 28022927 DOI: 10.1200/Jco.2011.29.15_Suppl.Tps127 |
0.425 |
|
| 2011 |
Voduc D, Cheang MC, Prat A, He X, Tyldesley S, Snider J, DeSchryver K, Davies S, Ellis MJ, Perou CM, Nielsen TO. The other triple-negative breast cancer: Immunohistochemical and clinicopathologic characterization of the Claudin-low subtype. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1129. PMID 28021529 DOI: 10.1200/Jco.2011.29.15_Suppl.1129 |
0.604 |
|
| 2011 |
Prat A, Parker JS, Fan C, Cheang MC, Miller LD, Bergh J, Chia SK, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Concordance among gene-expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 502. PMID 28021373 DOI: 10.1200/jco.2011.29.15_suppl.502 |
0.499 |
|
| 2011 |
Liu H, Bockhorn J, Dalton R, Dolan ME, Perou CM, Olopade OI, Clarke MF, Greene G. Roles of miRNAs in breast cancer stem cells, drug sensitivity, and spontaneous metastases in orthotopic human-in-mouse models. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1082. PMID 28021259 DOI: 10.1200/Jco.2011.29.15_Suppl.1082 |
0.507 |
|
| 2011 |
Cheang MC, Voduc D, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, Levine MN, Pritchard KI, Vickery T, Davies S, Stijleman IJ, Davis C, Parker JS, Ellis MJ, ... ... Perou CM, et al. The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1032. PMID 28020707 DOI: 10.1200/Jco.2011.29.15_Suppl.1032 |
0.496 |
|
| 2011 |
Bernard PS, Davis C, Munarriz B, Stijleman IJ, Ruiz-Borrego M, Ebbert MT, Rodriguez-Lescure A, Bastien RR, Crespo C, Perou CM, Rodriguez C, Aranda FI, Furió V, Alvarez I, Seguí MA, et al. Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 611. PMID 28020639 DOI: 10.1200/Jco.2011.29.15_Suppl.611 |
0.447 |
|
| 2011 |
Haakensen VD, Lingjaerde OC, Lüders T, Riis M, Prat A, Troester MA, Holmen MM, Frantzen JO, Romundstad L, Navjord D, Bukholm IK, Johannesen TB, Perou CM, Ursin G, Kristensen VN, et al. Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features. Bmc Medical Genomics. 4: 77. PMID 22044755 DOI: 10.1186/1755-8794-4-77 |
0.536 |
|
| 2011 |
Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, ... ... Perou CM, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nature Genetics. 43: 1210-4. PMID 22037553 DOI: 10.1038/Ng.985 |
0.5 |
|
| 2011 |
Abell AN, Jordan NV, Huang W, Prat A, Midland AA, Johnson NL, Granger DA, Mieczkowski PA, Perou CM, Gomez SM, Li L, Johnson GL. MAP3K4/CBP-regulated H2B acetylation controls epithelial-mesenchymal transition in trophoblast stem cells. Cell Stem Cell. 8: 525-37. PMID 21549327 DOI: 10.1016/J.Stem.2011.03.008 |
0.403 |
|
| 2011 |
Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, Herschkowitz JI, Egan SE, Perou CM, Zacksenhaus E. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle (Georgetown, Tex.). 10: 1563-70. PMID 21502814 DOI: 10.4161/Cc.10.10.15703 |
0.801 |
|
| 2011 |
Anders CK, Deal AM, Miller CR, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA. The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer. 117: 1602-11. PMID 21472708 DOI: 10.1002/Cncr.25746 |
0.481 |
|
| 2011 |
Martin M, Romero A, Cheang MC, López GarcÃa-Asenjo JA, GarcÃa-Saenz JA, Oliva B, Román JM, He X, Casado A, de la Torre J, Furio V, Puente J, Caldés T, Vidart JA, Lopez-Tarruella S, ... ... Perou CM, et al. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer. Breast Cancer Research and Treatment. 128: 127-36. PMID 21465170 DOI: 10.1007/S10549-011-1461-Y |
0.528 |
|
| 2011 |
Dunbier AK, Anderson H, Ghazoui Z, Salter J, Parker JS, Perou CM, Smith IE, Dowsett M. Association between breast cancer subtypes and response to neoadjuvant anastrozole. Steroids. 76: 736-40. PMID 21447351 DOI: 10.1016/J.Steroids.2011.02.025 |
0.659 |
|
| 2011 |
Romero A, Martín M, Cheang MC, López García-Asenjo JA, Oliva B, He X, de la Hoya M, García Sáenz JÁ, Arroyo Fernández M, Díaz Rubio E, Perou CM, Caldés Llopis T. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. The American Journal of Pathology. 178: 1453-60. PMID 21435434 DOI: 10.1016/J.Ajpath.2010.12.042 |
0.587 |
|
| 2011 |
Perou CM. Molecular stratification of triple-negative breast cancers. The Oncologist. 16: 61-70. PMID 21278442 DOI: 10.1634/theoncologist.2011-S1-61 |
0.529 |
|
| 2011 |
Fan C, Prat A, Parker JS, Liu Y, Carey LA, Troester MA, Perou CM. Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. Bmc Medical Genomics. 4: 3. PMID 21214954 DOI: 10.1186/1755-8794-4-3 |
0.685 |
|
| 2011 |
Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Molecular Oncology. 5: 5-23. PMID 21147047 DOI: 10.1016/J.Molonc.2010.11.003 |
0.582 |
|
| 2011 |
Camp JT, Elloumi F, Roman-Perez E, Rein J, Stewart DA, Harrell JC, Perou CM, Troester MA. Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers. Molecular Cancer Research : McR. 9: 3-13. PMID 21131600 DOI: 10.1158/1541-7786.Mcr-10-0372 |
0.555 |
|
| 2011 |
Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL, Klauber-DeMore N, Perou CM. Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: e18-20. PMID 21115855 DOI: 10.1200/Jco.2010.28.9199 |
0.589 |
|
| 2011 |
Perou CM, Børresen-Dale AL. Systems biology and genomics of breast cancer. Cold Spring Harbor Perspectives in Biology. 3. PMID 21047916 DOI: 10.1101/Cshperspect.A003293 |
0.626 |
|
| 2011 |
Giulianelli S, Herschkowitz JI, Patel V, Lamb CA, Gutkind JS, Molinolo A, Perou CM, Lanari C. MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. Breast Cancer Research and Treatment. 129: 49-67. PMID 20890655 DOI: 10.1007/S10549-010-1185-4 |
0.744 |
|
| 2011 |
Perou CM. Comparative genomic analysis of mouse and human mammary tumors Genome Biology. 12: I12. DOI: 10.1186/Gb-2011-12-S1-I12 |
0.457 |
|
| 2011 |
Prat A, Perou C. Molecular classification of triple-negative tumors Breast Cancer Research. 13: 1-9. DOI: 10.1186/Bcr3001 |
0.595 |
|
| 2011 |
Bild AH, Parker JS, Gustafson AM, Acharya CR, Hoadley KA, Anders C, Marcom PK, Carey LA, Potti A, Nevins JR, Perou CM. Correction: An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer Breast Cancer Research. 13. DOI: 10.1186/bcr2909 |
0.739 |
|
| 2011 |
Richards KL, Motsinger-Reif A, Chen H, Fedoriw YD, Fan C, Nielsen DM, Thomas R, Smith C, Dave SS, Perou CM, Breen M, Suter SE. Characterizing Canine Lymphoma As a Potential Large Animal Model of Human Diffuse Large B-Cell Lymphoma Blood. 118: 5193-5193. DOI: 10.1182/Blood.V118.21.5193.5193 |
0.355 |
|
| 2011 |
Ellis MJ, Ding L, Shen D, Wallis J, Suman V, Luo J, Tao Y, Hoog J, Davies S, Lin L, Perou C, Tine BV, Bose R, Chang LW, Chen K, et al. Abstract LB-87: Analysis of luminal-type breast cancer by massively parallel sequencing Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-87 |
0.567 |
|
| 2011 |
Ferree S, Bernard PS, Dowidar N, Ellis M, Maysuria M, Nielsen T, Payandeh E, Parker J, Perou CM, Storhoff J, Wallden B. Abstract LB-327: Analytical performance of the nCounter analysis system for gene expression cancer signatures Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-327 |
0.489 |
|
| 2011 |
Smith SM, Chiao LJ, Nogueria L, Usary J, Perou CM, Varticovski L, Hursting SD. Abstract 3332: Obesity drives epithelial/mesenchymal transition and tumor progression in a novel Wnt-1 mammary cancer model Cancer Research. 71: 3332-3332. DOI: 10.1158/1538-7445.Am2011-3332 |
0.516 |
|
| 2011 |
Dunlap S, Chiao L, Nogueria L, Usary J, Perou C, Varticovski L, Hursting S. S6-5: Obesity Drives Epithelial-to-Mesenchymal Transition and Tumor Progression in a Novel Claudin-Low Mammary Cancer Model. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S6-5 |
0.479 |
|
| 2011 |
Cook R, Balko J, Rinehart C, Miller T, Polyak K, Prat A, Perou C, Arteaga C. S2-6: ErbB3 Expression Is Required for Maintenance of Normal and Transformed Luminal Breast Epithelial Cells. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-S2-6 |
0.581 |
|
| 2011 |
Chao H, He X, Perou C. PD03-06: Basal-Like Breast Tumors Are Associated with Frequent Micro Genomic Aberrations in Important Cancer Genes. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-Pd03-06 |
0.544 |
|
| 2011 |
Usary J, Darr D, Zhao W, Balletta L, Aparicio A, Karginova O, Jordan J, Perou C. P4-03-03: Therapeutic Sensitivities of Mouse Models of Human Breast Cancer. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P4-03-03 |
0.515 |
|
| 2010 |
O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, Dressler LG, Geradts J, Millikan RC. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 6100-10. PMID 21169259 DOI: 10.1158/1078-0432.Ccr-10-1533 |
0.569 |
|
| 2010 |
Irvin WJ, Orlowski RZ, Chiu WK, Carey LA, Collichio FA, Bernard PS, Stijleman IJ, Perou C, Ivanova A, Dees EC. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clinical Breast Cancer. 10: 465-70. PMID 21147690 DOI: 10.3816/Cbc.2010.N.061 |
0.504 |
|
| 2010 |
Perou CM. Molecular stratification of triple-negative breast cancers. The Oncologist. 15: 39-48. PMID 21138954 DOI: 10.1634/Theoncologist.2010-S5-39 |
0.607 |
|
| 2010 |
Thorner AR, Parker JS, Hoadley KA, Perou CM. Potential tumor suppressor role for the c-Myb oncogene in luminal breast cancer. Plos One. 5: e13073. PMID 20949095 DOI: 10.1371/Journal.Pone.0013073 |
0.836 |
|
| 2010 |
Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5222-32. PMID 20837693 DOI: 10.1158/1078-0432.Ccr-10-1282 |
0.677 |
|
| 2010 |
Van Loo P, Nordgard SH, Lingjærde OC, Russnes HG, Rye IH, Sun W, Weigman VJ, Marynen P, Zetterberg A, Naume B, Perou CM, Børresen-Dale AL, Kristensen VN. Allele-specific copy number analysis of tumors. Proceedings of the National Academy of Sciences of the United States of America. 107: 16910-5. PMID 20837533 DOI: 10.1073/Pnas.1009843107 |
0.532 |
|
| 2010 |
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Research : Bcr. 12: R68. PMID 20813035 DOI: 10.1186/Bcr2635 |
0.842 |
|
| 2010 |
Wang K, Singh D, Zeng Z, Coleman SJ, Huang Y, Savich GL, He X, Mieczkowski P, Grimm SA, Perou CM, MacLeod JN, Chiang DY, Prins JF, Liu J. MapSplice: accurate mapping of RNA-seq reads for splice junction discovery. Nucleic Acids Research. 38: e178. PMID 20802226 DOI: 10.1093/Nar/Gkq622 |
0.36 |
|
| 2010 |
Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Clinical implementation of the intrinsic subtypes of breast cancer. The Lancet. Oncology. 11: 718-9; author reply . PMID 20688274 DOI: 10.1016/S1470-2045(10)70176-5 |
0.659 |
|
| 2010 |
Jiang Z, Deng T, Jones R, Li H, Herschkowitz JI, Liu JC, Weigman VJ, Tsao MS, Lane TF, Perou CM, Zacksenhaus E. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. The Journal of Clinical Investigation. 120: 3296-309. PMID 20679727 DOI: 10.1172/Jci41490 |
0.776 |
|
| 2010 |
Stratford JK, Bentrem DJ, Anderson JM, Fan C, Volmar KA, Marron JS, Routh ED, Caskey LS, Samuel JC, Der CJ, Thorne LB, Calvo BF, Kim HJ, Talamonti MS, Iacobuzio-Donahue CA, ... ... Perou CM, et al. A six-gene signature predicts survival of patients with localized pancreatic ductal adenocarcinoma. Plos Medicine. 7: e1000307. PMID 20644708 DOI: 10.1371/Journal.Pmed.1000307 |
0.371 |
|
| 2010 |
Wilkerson MD, Yin X, Hoadley KA, Liu Y, Hayward MC, Cabanski CR, Muldrew K, Miller CR, Randell SH, Socinski MA, Parsons AM, Funkhouser WK, Lee CB, Roberts PJ, Thorne L, ... ... Perou CM, et al. Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically important, and correspond to normal cell types. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4864-75. PMID 20643781 DOI: 10.1158/1078-0432.Ccr-10-0199 |
0.591 |
|
| 2010 |
Deisenroth C, Thorner AR, Enomoto T, Perou CM, Zhang Y. Mitochondrial Hep27 is a c-Myb target gene that inhibits Mdm2 and stabilizes p53. Molecular and Cellular Biology. 30: 3981-93. PMID 20547751 DOI: 10.1128/Mcb.01284-09 |
0.647 |
|
| 2010 |
Pond AC, Herschkowitz JI, Schwertfeger KL, Welm B, Zhang Y, York B, Cardiff RD, Hilsenbeck S, Perou CM, Creighton CJ, Lloyd RE, Rosen JM. Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. Cancer Research. 70: 4868-79. PMID 20501844 DOI: 10.1158/0008-5472.Can-09-4404 |
0.755 |
|
| 2010 |
Prat A, Perou CM. WITHDRAWN: Deconstructing the molecular portraits of breast cancer. Molecular Oncology. PMID 20447881 DOI: 10.1016/J.Molonc.2010.04.003 |
0.538 |
|
| 2010 |
Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 17: 510-22. PMID 20399149 DOI: 10.1016/J.Ccr.2010.03.017 |
0.597 |
|
| 2010 |
Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW, Harris CC, McLellan MD, Fulton RS, Fulton LL, Abbott RM, Hoog J, Dooling DJ, Koboldt DC, Schmidt H, ... ... Perou CM, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature. 464: 999-1005. PMID 20393555 DOI: 10.1038/Nature08989 |
0.413 |
|
| 2010 |
Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G, Lawrence M, O'Kelly M, Tamayo P, Weir BA, ... ... Perou CM, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17: 98-110. PMID 20129251 DOI: 10.1016/J.Ccr.2009.12.020 |
0.623 |
|
| 2010 |
Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M. Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 1161-7. PMID 20124184 DOI: 10.1200/Jco.2009.23.9616 |
0.642 |
|
| 2010 |
Sikov WM, Perou CM, Golshan M, Collyar D, Berry DA, Hahn OM, Singh B, Hudis C, Winer EP. Randomized phase II trial of adding carboplatin and/or bevacizumab to neoadjuvant weekly paclitaxel and dose-dense AC in triple-negative breast cancer. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.Tps110 |
0.505 |
|
| 2010 |
Chia SK, Ung K, Bramwell VH, Tu D, Perou CM, Ellis MJ, Bernard PS, Vickery T, Shepherd LE, Nielsen TO. Prognostic and predictive impact of biologic classification by qRT-PCR with a 50-gene subtype predictor (PAM50) for adjuvant tamoxifen in premenopausal breast cancer: Results from the NCIC CTG MA.12 randomized trial. Journal of Clinical Oncology. 28: 508-508. DOI: 10.1200/Jco.2010.28.15_Suppl.508 |
0.571 |
|
| 2010 |
Martin M, Romero A, Lopez Garcia-Asenjo J, Cheang MC, Oliva B, Garcia Saenz J, He X, Caldes T, Diaz-Rubio E, Perou CM. Molecular and genomic predictors of response to single-agent doxorubicin (ADR) versus single-agent docetaxel (DOC) in primary breast cancer (PBC). Journal of Clinical Oncology. 28: 502-502. DOI: 10.1200/Jco.2010.28.15_Suppl.502 |
0.409 |
|
| 2010 |
Grushko TA, Nwachukwu C, Charoenthammaraksa S, Huo D, Khramtsov A, Mashek H, Zhang C, Xu J, Perou CM, Olopade OI. Evaluation of BRCA1 inactivation by promoter methylation as a marker of triple-negative and basal-like breast cancers. Journal of Clinical Oncology. 28: 10510-10510. DOI: 10.1200/Jco.2010.28.15_Suppl.10510 |
0.575 |
|
| 2010 |
Anders CK, Deal AM, Khorram C, Meng H, Burrows E, Livasy C, Fritchie K, Ewend MG, Perou CM, Carey LA. The prognostic contribution of intrinsic breast cancer subtype, race, and age among patients with brain metastases. Journal of Clinical Oncology. 28: 1027-1027. DOI: 10.1200/Jco.2010.28.15_Suppl.1027 |
0.488 |
|
| 2010 |
Herschkowitz JI, Zhang M, Zhaow W, Murrow GW, Edwards D, Knezevic J, Greene SB, Medina D, Perou CM, Rosen JM. Abstract 4212: p53 null spindloid murine mammary tumors show features associated with human claudin-low tumors and enrichment for cancer stem cells Cancer Research. 70: 4212-4212. DOI: 10.1158/1538-7445.Am10-4212 |
0.488 |
|
| 2010 |
Nwachukwu C, Zhang C, Duan S, Huo D, Minn A, Perou C, Olopade O. Abstract 3004: Specific microRNAs associate with aggressive breast tumor phenotypes in an ethnically diverse patient cohort Cancer Research. 70: 3004-3004. DOI: 10.1158/1538-7445.Am10-3004 |
0.476 |
|
| 2010 |
Wilkerson MD, Yin X, Hayward MC, Funkhouser WK, Thorne L, Parsons AM, Miller CR, Socinski MA, Bernard PS, Perou CM, Hayes DN. Abstract 2164: Lung adenocarcinoma subtypes have unique gene mutations (EGFR, TP53), DNA copy number alterations (3q26, 16p13), and patient smoking histories Cancer Research. 70: 2164-2164. DOI: 10.1158/1538-7445.Am10-2164 |
0.39 |
|
| 2010 |
Perou C. Abstract ES7-2: Next Generation Sequencing for the Clinician Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-Es7-2 |
0.386 |
|
| 2010 |
Van Loo P, Nordgard S, Lingjærde O, Russnes H, Rye I, Sun W, Naume B, Perou C, Børresen-Dale A, Kristensen V. 794 Allele-specific copy number analysis of breast carcinomas European Journal of Cancer Supplements. 8: 200. DOI: 10.1016/S1359-6349(10)71590-1 |
0.446 |
|
| 2009 |
Prat A, Karginova O, Fan C, Perou CM. Notch-associated expression profiles in basal-like and claudin-low breast cancer molecular subtypes. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11017. PMID 27963972 DOI: 10.1200/Jco.2009.27.15_Suppl.11017 |
0.575 |
|
| 2009 |
DeMichele A, Dunn L, Gimotty P, Livasy C, Perou C, Carey L, Esserman L. Loss of p27 expression and response to neoadjuvant chemotherapy: Results from the I-SPY Trial (CALGB150007/150012, ACRIN6657). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 11091. PMID 27963119 DOI: 10.1200/Jco.2009.27.15_Suppl.11091 |
0.466 |
|
| 2009 |
Kennecke HF, Voduc D, Leung S, Cryns VL, Perou CM, Nielsen TO, Cheang M. α-basic-crystallin expression in basal-like breast cancer and its association with brain metastasis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1025. PMID 27961038 DOI: 10.1200/Jco.2009.27.15_Suppl.1025 |
0.477 |
|
| 2009 |
Troester MA, Lee MH, Carter M, Fan C, Cowan DW, Perez ER, Pirone JR, Perou CM, Jerry DJ, Schneider SS. Activation of host wound responses in breast cancer microenvironment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 7020-8. PMID 19887484 DOI: 10.1158/1078-0432.Ccr-09-1126 |
0.555 |
|
| 2009 |
Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, Grushko T, Zhang C, Oluwasola O, Malaka D, Malami S, Odetunde A, Adeoye AO, Iyare F, ... ... Perou CM, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4515-21. PMID 19704069 DOI: 10.1200/Jco.2008.19.6873 |
0.496 |
|
| 2009 |
Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, Cole MD. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. Plos One. 4: e6693. PMID 19690609 DOI: 10.1371/Journal.Pone.0006693 |
0.508 |
|
| Show low-probability matches. |